US20110172180A1 - Heat stable hyaluronic acid compositions for dermatological use - Google Patents
Heat stable hyaluronic acid compositions for dermatological use Download PDFInfo
- Publication number
- US20110172180A1 US20110172180A1 US12/714,377 US71437710A US2011172180A1 US 20110172180 A1 US20110172180 A1 US 20110172180A1 US 71437710 A US71437710 A US 71437710A US 2011172180 A1 US2011172180 A1 US 2011172180A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- dermal filler
- gel
- additional ingredient
- juvederm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
Definitions
- Skin aging is a progressive phenomenon, occurs over time and can be affected by lifestyle factors, such as alcohol consumption, tobacco and sun exposure. Aging of the facial skin can be characterized by atrophy, slackening, and fattening. Atrophy corresponds to a massive reduction of the thickness of skin tissue. Slackening of the subcutaneous tissues leads to an excess of skin and ptosis and leads to the appearance of drooping cheeks and eye lids. Fattening refers to an increase in excess weight by swelling of the bottom of the face and neck. These changes are typically associated with dryness, loss of elasticity, and rough texture.
- a variety of compounds can have an effect on the skin such as wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant effects.
- various vitamins as well and hyaluronic acid (HA) are known to have an effect on skin.
- Vitamin C is the L-enantiomer of ascorbate and has a well-described role in collagen development. Vitamin C is involved in the hydroxylation of collagen, which allows it to assume its triple-helix structure. Vitamin C is also known for its antioxidant effects and is well tolerated.
- HA is a natural polysaccharide.
- Hyaluronic acid represents a natural constituent of the dermis, where it plays an important role in the hydration and elasticity of skin. There is a strong correlation between the water content in the skin and levels of HA in the dermal tissue. As skin ages, the amount and quality of HA in the skin is reduced. These changes lead to drying and wrinkling of the skin.
- HA is tolerated well and there is no immunogenicity associated with its use.
- the low incidence of side effects has lead to the use of HA for the treatment of wrinkles, fine lines, and scars.
- HA is subject to degradation through different pathways (e.g. enzymatic, temperature, free radicals), and therefore, its longevity in vivo is limited.
- HA hyaluronic acid
- U.S. Pat. No. 6,921,819 a process for cross-linking solid hyaluronic acid (HA) by reacting it with a polyfunctional linker during hydration of the HA
- U.S. Pat. No. 6,685,963 acrylic particles of HA
- U.S. publication 200610194758 a method for making a hydrogel by cross linking high and low molecular weight sodium HAs
- U.S. publication 2009/0036403 cross-linking HA with a tetra functional PEG epoxide to provide “tunably” cross-linked HA
- U.S. publications 2009/0143331 (a HA dermal filler with a degradation inhibitor, such as chondroitin sulphate, in order to provide a longer lasting filler); U.S. publication 2009/0143348 (HA combined with a steroid); and U.S. publication 2009/0155314 (HA combined with a botulinum toxin). Additionally, U.S. publications 2009/0148527, 2009/0093755, and 2009/0022808 disclose HA in microspheres, cross-linked with collagen, and coated with a protein, respectively.
- a degradation inhibitor such as chondroitin sulphate
- HA include: WO 2009/034559 (a process for aesthetic and/or reparative treatment of the skin with compositions that contain at least one C-glycoside derivative); WO 2009/024719 (cosmetic and pharmaceutical compositions that contain HA and a C-glycoside derivative useful for filling recesses/depressions in the skin, restore volume of the body or the face, and to reduce the sign of aging); WO 2007/128923 (a method for preparing a biocompatible gel with controlled release of one or more active lipophilic and/or amphiphilic ingredients); U.S.
- U.S. Pat. No. 3,763,009 a process for improving the oxidation resistance of ascorbic acid by subjecting a mixture of ascorbic acid, maltose and/or oligosaccharides to an enzyme derived from genera Aspergillus, Penicillium or others to enzymatically convert the mixture into ascorbic acid glucoside
- 5,616,611 a ⁇ -Glycosyl-L-ascorbic acid that exhibits no direct reducing activity, is stable, and is useful as a stabilizer, quality-improving agent, antioxidant, physiologically active agent, a UV-absorbant in pharmaceutical and cosmetic industries
- U.S. Pat. No. 5,843,907 the production and use of a crystalline 2-O- ⁇ -D-glucopyranosyl-L-ascorbic acid suitable for vitamin C enriching agents, food stuffs, pharmaceuticals, and cosmetics
- EP 0539196 an industrial scale preparation of high purity 2-O- ⁇ -D-glucopyranosyl-L-ascorbic acid
- Commercial products incorporating HA and/or vitamin C agents include: MESOGLOW® products, REVITACARE®, and NCTF® 135/135HA Mesotherapy products.
- Our invention includes a stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of a wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredient.
- Stability of the dermal filler formulation can be determined by subjecting the dermal filler formulation to a heat treatment selected from the group consisting of (a) steam sterilization (equivalently “autoclaving”) and (b) about 32 days at about 45° C., with substantial retention after the heat treatment of one or more of the dermal filler characteristics of being clear, homogenous, and cohesive, and without substantial degradation of the dermal filler formulation after the heat treatment.
- a heat treatment selected from the group consisting of (a) steam sterilization (equivalently “autoclaving”) and (b) about 32 days at about 45° C.
- the steam sterilization is carried out at a temperature of at least about 120° C., as we have found that a high temperature steam sterilization reduces the sterilization time required while still providing all sterility requirements, without degradation of the dermal filler formulation occurring when the additional ingredients set forth herein are present in the formulation. More preferably, the steam sterilization is carried out at a temperature between about 130° C. and 135° C., because we found that such a particular high temperature steam sterilization not only further reduces the sterilization time required while still providing all sterility requirements but as well can be carried out with little or no degradation of the dermal filler formulation occurring. Preferably, the steam sterilization is carried out for between about one minute and about 10 minutes and more preferably for between about 1 minute and about 5 minutes.
- Our invention also includes a steam sterilization stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredients, wherein the formulation is substantially clear (i.e. little or no modification of the pre-heat [i.e. steam] treatment dermal filler formulation color occurs as compared to the color of the post heat treatment dermal filler formulation), homogenous, cohesive stable and not substantially degraded after steam sterilization.
- HA hyaluronic acid
- Degradation can be shown after steam sterilization by, for example, discoloration of the steam sterilized dermal filler formation and/or by a decrease in the homogeneity of the formulation or in other formulation rheological properties.
- Substantially clear means that on visual inspection the dermal filler formulation both before and after steam sterilization is not opaque.
- Substantially homogenous means the dermal filler formulation both before and after steam sterilization has the same consistency (eg well mixed throughout).
- Substantially monophasic means the dermal filler formulation both before and after steam sterilization comprises only one phase, meaning it is a gel with no particles.
- Substantially cohesive means the ability of the dermal filler formulation both before and after steam sterilization to retain its shape and resist deformation.
- Cohesiveness is affected by, among other factors, the molecular weight ratio of the initial free HA, the degree of crosslinking, the amount of residual free HA following crosslinking, and the ph of the dermal filler formulation. Moreover, a cohesive dermal filler formulation resists phase separation when tested according to the method disclosed by Example 1A herein.
- our dermal filler formulations are stable after steam sterilization (i.e. at a temperature between about 120° C. to 135° C. or greater). Additionally our dermal filler formulations have long term storage or shelf life stability as shown for example by maintenance of stability of the dermal filler formulations in an environment at about 45° C. for about 32 days (accelerated heat testing), which can be considered to show that stability will be maintained for about 1 to 3 years at room temperature; stability can be determined by substantial retention at room temperature of one or more of the dermal filler characteristics of being clear, homogenous, and cohesive, and without substantial degradation of the dermal filler formulation. Stability of our dermal filler formulations can be determined over a period of or about 25 days to about 35 days at a temperature of about 35° to 50 C.
- the accelerated heat stability testing is carried out for about 32 days at about 45° C.
- Substantially stable after the accelerated heat (stability) testing carried out as set forth above, or substantially stable after autoclaving or after steam sterilization of the dermal filler formulation means the dermal filler formulation retains (as being resistant to degradation) at least 80% and preferably at least 90% and most preferably at least about 95% of at least one of its measured characteristics of transparency, pH, extrusion force, rheological characteristics, hyaluronic acid (HA) concentration, sterility, osmolarity, and same additional ingredient concentration.
- the HA is preferably cross-linked and the HA can be present in an amount of about 1 to about 40 mg/mL.
- An additional ingredient in our dermal filler formulation can be a vitamin B, C or E and the additional ingredient can be present in an amount of about 0.001% to about 10% w/w, and preferably be present in an amount of from about 0.1% to about 3% w/w.
- the additional ingredient can provide the dermal filler formulation with improved rheological properties resulting in less extrusion force required for administration compared to an HA gel formulation without the additional constituent.
- Our invention also includes a method for treating a dermal condition such as fine lines, wrinkles, fibroblast depletions, and/or scars of a patient by administering to the patient an effective amount of a steam sterilization stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredients, wherein the formulation is clear, homogenous, cohesive, stable and not degraded after steam sterilization and wherein the appearance of the fine lines, wrinkles, fibroblast depletions, or scars is diminished.
- the administration can be by sub dermal, intra-dermal or subcutaneous injected (i.e. local injection administration) into a facial skin of the subject.
- Our invention also includes a steam sterilization stable dermal filler formulation comprising a hyaluronic acid and at least one additional ingredient selected from the group consisting of AA2G and dexpanthenol, wherein the stability of the dermal filler formulation is significantly increased by the additional ingredient—as shown by the dermal filler formulation having a ⁇ Tan ⁇ 1 Hz ⁇ 0.05.
- FIG. 1 is a representation of the structure of an ascorbyl-2-glucoside, also known as AA2GTM (Hayashibara Co., Japan).
- FIG. 2 is a graph showing the synthesis of pro-collagen (% control) for control, gel+lidocaine 0.3%, AA2GTM 0.6% in phosphate buffer, and gel+AA2GTM 0.6%+lidocaine 0.3%.
- FIG. 3 is a graph showing the extrusion force over time (3 yr equivalent at 25° C.) in compositions: control, AA2GTM plus lidocaine, and AA2GTM plus lidocaine and TPGS.
- FIG. 4 is a graph showing the pH over time (3 yr equivalent at 25° C.) in compositions: control, AA2GTM plus lidocaine, and AA2GTM plus lidocaine and TPGS.
- FIG. 5 is a graph of tan delta 1 Hz over time (3 yr equivalent at 25° C.) in compositions: control, AA2GTM plus lidocaine, and AA2GTM plus lidocaine and TPGS.
- FIG. 7 is a graph comparing antioxidant properties in compositions: control versus JUVEDERM® Ultra with lidocaine AA2GTM, and JUVEDERM® Ultra with lidocaine.
- a steam sterilization stable HA based dermal filler can be prepared with an additional ingredient (that is besides the HA present in the formation) which is a wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and/or anti-irritant ingredient.
- An HA dermal filler within the scope of our invention (“the dermal filler formulation”) is (autoclaving) steam sterilization stable and as demonstrated stability after about 32 days at about 45° C.
- the formulation does not exhibit any degradation as shown by the pre and post autoclaved formulations both being clear, homogenous, and cohesive.
- the dermal filler formulation can also exhibit greater stability than an HA gel formulation without the additional constituent.
- the matrix of the cross-linked HA used in our formulation sequesters renders non-reactive and thereby prevents the additional ingredient (as set forth for example in Examples 4-6, 10-11, 13, 15-16, 20, 24, and 25-29, supra) from degrading and causes degradation of the dermal filler formulation during steam sterilization.
- the additional ingredient can be hydrophilic and provides protection to the HA from degradation during steam sterilization and/or after administration of the dermal filler formulation to a patient.
- the incorporation of an additional ingredient in the dermal filler formulation may inhibit free-radical scavenging at the injection/implant site, thereby prolonging dermal filler duration after patient administration. After steam sterilization the additional ingredient can upon administration (as by subdermal injection) be released from the dermal filler formulation for cosmetic or therapeutic effect.
- Autoclave stable or steam sterilization stable as used herein means a dermal filler formulation that is resistant to degradation such that the formulation retains at least one, and preferably all, of the following aspects after steam sterilization: transparent or clear appearance pH, extrusion force and/or rheological characteristics, hyaluronic acid (HA) concentration, osmolarity, and same additional ingredient concentration.
- High molecular weight HA as used herein describes a HA material having a molecular weight of at least about 1.0 million Daltons (mw ⁇ 10 6 Da or 1 MDa) to about 4.0 MDa.
- the high molecular weight HA in the present compositions may have a molecular weight of about 2.0 MDa.
- the high molecular weight HA may have a molecular weight of about 2.8 MDa.
- Low molecular weight HA as used herein describes a HA material having a molecular weight of less than about 1.0 MDa.
- Low molecular weight HA can have a molecular weight of between about 200,000 Da (0.2 MDa) to less than about 1.0 MDa, for example, between about 300,000 Da (0.3 M Da) to about 750,000 Da. (0.75 MDa).
- Degree of crosslinking refers to the intermolecular junctions joining the individual HA polymer molecules, or monomer chains, into a permanent structure, or as disclosed herein the soft tissue filler composition. Moreover, degree of crosslinking for purposes of the present disclosure is further defined as the percent weight ratio of the crosslinking agent to HA-monomeric units within the crosslinked portion of the HA based composition. It is measured by the weight ratio of HA monomers to crosslinker (HA monomers:crosslinker).
- Free HA refers to individual HA polymer molecules that are not crosslinked to, or very lightly crosslinked to (very low degree of crosslinking) the highly crosslinked (higher degree of crosslinking) macromolecular structure making up the soft tissue filler composition. Free HA generally remains water soluble. Free HA can alternatively be defined as the “uncrosslinked,” or lightly crosslinked component of the macromolecular structure making up the soft tissue filler composition disclosed herein.
- the presence of an additional ingredient in the dermal filler formulation can provide a stability and longevity that is not exhibited in a dermal filler formulation containing HA without the additional ingredient.
- the disclosed formulations after steam sterilization are homogenous, uncolored, clear, cohesive gel.
- Our invention includes methods for treating dermatological conditions, such as fine lines, wrinkles, fibroblast depletions, and/or scars afflicting a subject by administering to a patient an effective amount of a the dermal filler formulation.
- the patient can be any mammal, preferably a human of any age, gender or race. Although typically a subject experiencing the signs of aging skin is an adult, subjects experiencing premature aging or other skin conditions suitable for treatment (for example, a scar) with the HA gel formulation can be treated as well.
- our dermal filler formulation comprise HA which is preferably at least partly cross-linked and can contain some not cross-linked HA.
- HA any pharmaceutically or cosmetically acceptable HA
- the preferred HA utilized includes those sold as JUVEDERM®, JUVEDERM® 30, JUVEDERM® Ultra Plus, JUVEDERM® Ultra injectable gel (Allergan Inc, Irvine, Calif.).
- the formulation comprises a HA gel matrix and an additional constituent.
- HA is a known hydrogel.
- the gel can be injectable, bioresorbable, monophasic, or biphasic.
- the additional constituent can be directly incorporated into the HA gel.
- the gel composition can include a biocompatible or biodegradable vessel.
- the HA gel can be made by any known, suitable methods.
- Cross-linked HA gels typically have high viscosity and require considerable force to extrude through a fine needle. Uncross-linked HA is often used as a lubricant to facilitate the extrusion process. However, especially in HA dermal fillers and implants, uncross-linked HA does not contribute to the persistence of the final product in vivo.
- the formulations exhibit increased stability compared to formulations containing HA without the additional constituent. Stability is determined by assessing the homogeneity, color, and clarity, pH, and rheological properties of the gel formulation.
- the formulations disclosed herein are considered stable if they remain homogenous, colorless, and/or clear, and exhibit stable pH and rheology. The disclosed formulations remain stable for at least about 6 months, at least about 1 year, at least about 2 years or at least about 3 years.
- a cross-linking agent can be used to cross-link the HA according to the present disclosure.
- the cross-linking agent may be any agent known to be suitable for cross-linking HA and its derivatives via hydroxyl groups.
- Suitable cross-linking agents include but are not limited to, 1,4-butanediol diglycidyl ether, 1,4-bis(2,3-epoxypropoxy)butane, and/or 1,4-bisglycidyloxybutane (commonly known as BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene, and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane.
- BDDE 1,4-butanediol diglycidyl ether
- 1,4-bis(2,3-epoxypropoxy)butane 1,4-bisglycidyloxybutane
- 1,2-bis(2,3-epoxypropoxy)ethylene 1,2-bis(2,3-ep
- Dermal fillers can be used to treat moderate to severe facial wrinkles and folds such as nasolabial folds (those lines that extend from the nose to the corners of the mouth).
- a dermal filler can be a gel implant formulation that includes HA and an additional constituent.
- the formulations disclosed herein can further include additional cosmetic agents that supplement and improve the appearance of skin.
- the cosmetic active ingredients may include, but are not limited to, antioxidants, vitamins, tension agents, and moisturizers.
- the formulations disclosed herein can be injected with a syringe into the mid to deep dermis of the face.
- the dermis is the subsurface skin layer that contains connective tissue, nerve endings, and blood vessels.
- the formulations, when administered as dermal fillers can improve skin appearance by lifting and adding volume to the wrinkles and folds in the treatment area. Further, in certain embodiments, improvement can be seen due to increased collagen production that results from administration of the formulation.
- cosmetic is an adjective referring to improving the appearance of a surface or covering defects.
- cosmetic compositions can be used to improve aesthetic rather than functional aspects of a surface.
- cosmetic compositions are formulated for application as a health and beauty treatment or for affecting personal appearance of the body, for example, keratinous surfaces such as skin, hair, nails, and the like.
- formulation and “composition” may be used interchangeably and refer to a combination of elements that is presented together for a given purpose. Such terms are well known to those of ordinary skill in the art.
- agents which can be included in the present dermal filler formulations are anti-itch, anti-cellulite, anti-scarring, and anti-inflammatory agents, anesthetics, anti-irritants, vasoconstrictors, vasodilators, as well as agents to prevent/stop bleeding, and improve/remove pigmentation, moisturizers, desquamating agents, tensioning agents, anti-acne agents.
- Anti-itch agents can include methyl sulphonyl methane, sodium bicarbonate, calamine, allantoin, kaolin, peppermint, tea tree oil, camphor, menthol, hydrocortisone and combinations thereof.
- Anti-cellulite agents can include forskolin, xanthine compounds such as, but not limited to, caffeine, theophylline, theobromine, and aminophylline, and combinations thereof.
- Anesthetic agents can include lidocaine, benzocaine, butamben, dibucaine, oxybuprocaine, pramoxine, proparacaine, proxymetacaine, tetracaine, and combinations thereof.
- Anti-scarring agents can include IFN-.gamma., fluorouracil, poly(lactic-co-glycolic acid), methylated polyethylene glycol, polylactic acid, polyethylene glycol and combinations thereof.
- Anti-inflammatory agents can include dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, cetirizine, diphenhydramine, antipyrine, methyl salicylate, loratadine, and derivatives and combinations thereof. Additionally, active agents such as epinephrine, thymidine, cytidine, uridine, antiypyrin, aminocaproic acid, tranexamic acid, eucalyptol, allantoin, glycerin, and sodium selenite, can be included.
- the disclosed dermal filler formulations can further comprise degradation inhibitors.
- Degradation inhibitors include but are not limited to, glycosaminoglycans (e.g., heparin, heparin sulfate, dermatan sulfate, chrondroitin sulfate, o-sulfated HA, Inamarin, glucosamine, and amygdalin), antioxidants (e.g.
- the additional ingredient can be an antioxidant.
- the antioxidant comprises a vitamin C such as ascorbyl-2-glucoside (available as AA2GTM. Hayashibara Co., Japan) ( FIG.
- Anti-irritants can include thymol, bisabolol.
- Healing agents can include allantoin, eucalyptol, chitosane, cytidine, thimidine, uridine, lanoline.
- Anti-bleeding epinephrine, norepinephrine, phenylephrine, synephrine, naphazoline, aminocaproic acid, tranexamic acid, ethamsylate, vitamin K.
- Collagen promoters can include retinol, peptide sequences.
- active ingredients such as epinephrine, thymidine, cytidine, uridine, antiypyrine, aminocaproic acid, eucalyptol, sodium selenite, can be included.
- the HA is present at a concentration of about 1 to about 40 mg/mL, or about 10 to about 40 mg/mL, or about 20 to about 30 mg/mL. In certain embodiments, the HA is present in a concentration of about 20 to about 25 mg/mL. In certain embodiments, the HA is present at a concentration of 24 mg/mL.
- the additional constituent can be present in an amount of about 0.001 to about 10% w/w, or from about 0.001 to about 5% w/w, or from 0.3 to about 3% w/w.
- the disclosure provides a dermal filler comprising (a) about 90 wt %, or about 95 wt %, or about 100 wt % of a high molecular weight (about 1 million to about 3 million Daltons) HA; and (b) 0 wt %, or about 5 wt %, or about 10 wt % of a low molecular weight (less than 1 million Daltons) HA.
- the HA is present in the dermal filler at a concentration of about 10 to about 24 mg HA/mL dermal filler and the HA is about 4% to about 11% cross-linked.
- the cross linker is 4-butane diol diglycidyl ether (BDDE).
- the dermal filler can further comprise about 0.1 wt % or 0.6 wt %, or 1.0 wt % of an ascorbyl-2-glucoside, such as AA2GTM (Hayashibara, Japan).
- AA2GTM ascorbyl-2-glucoside
- 0.6 wt % AA2GTM i.e., 6 mg AA2GTM/g HA
- Topical formulations of AA2GTM are known. However, there are no subdermally administered formulations of AA2GTM available, which is likely due to the fact that a topical AA2GTM is not thought to lend itself to an injectable formulation.
- the disclosure provides the first injectable formulation of AA2GTM that is efficacious, compatible, and stable over time.
- compositions are also well suited for mesotherapy.
- Mesotherapy is a non-surgical cosmetic treatment technique involving intra-epidermal, intra-dermal, and/or subcutaneous injection of an agent (micronutrients, vitamins, mineral salts, etc).
- agent micronutrients, vitamins, mineral salts, etc.
- the compositions are administered in the form of small multiple droplets into the epidermis, dermo-epidermal junction, and/or the dermis.
- the formulations of the disclosure can be injected utilizing needles with a diameter of about 0.26 to about 0.4 mm and a length ranging from about 4 to about 14 mm.
- the needles can be 21 to 32 G and have a length of about 4 mm to about 70 mm.
- the needle is a single-use needle.
- the needle can be combined with a syringe, catheter, and/or a pistol (for example, a hydropneumatic-compression pistol).
- the formulations can be administered once or over several sessions with the subject spaced apart by a few days, or weeks.
- the subject can be administered a formulation every 1, 2, 3, 4, 5, 6, 7, days or every 1, 2, 3, or 4, weeks.
- the administration can be on a monthly or bi-monthly basis. Further, the formulation can be administered every 3, 6, 9, or 12 months.
- Our dermal filler formulation can optionally include one or more agents such as, without limitation, emulsifying agents, wetting agents, sweetening or flavoring agents, tonicity adjusters, preservatives, buffers antioxidants and flavonoids.
- Tonicity adjustors useful in a pharmaceutical composition of the present disclosure include, but are not limited to, salts such as sodium acetate, sodium chloride, potassium chloride, mannitol or glycerin and other pharmaceutically acceptable tonicity adjusters.
- Preservatives useful in the dermal filler formulation described herein include, without limitation, benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercuric acetate, and phenyl mercuric nitrate.
- Various buffers and means for adjusting pH can be used to prepare the dermal filler formulation, including but not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers.
- antioxidants useful in the dermal filler formulation include for example, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
- Flavonoids are compounds found in plants that are well known to have diverse beneficial biochemical and antioxidant effects. Subcategories of flavonoids include: flavones, flavonols, flavanonse and flavanonols.
- flavonoids examples include: luteolin, apigenin, tangeritin, quercetin, kaempferol, myricetin, fisetin, isorhamnetin, pachypodol, rhamnazin, hesperetin, naringenin, eriodictyol, homoeriodictyol, taxifolin, dihydroquercetin, dihydrokaempferol, tannic acid, tannis, condensed tannis, and hydrolysable tannis. It is understood that these and other substances known in the art can be included in the dermal filler formulations disclosed herein.
- the pH of the disclosed dermal filler formulations can be about 5.0 to about 8.0, or about 6.5 to about 7.5. In certain embodiments, the pH of the formulation is about 7.0 to about 7.4 or about 7.1 to about 7.3.
- a dermal filler formulation must be capable of withstanding sterilization which is a strict requirement before the product can be sold (the product must be sterile). Sterilization can be carried out by steam sterilization, filtration, microfiltration, gamma radiation, ETO light or by a combination of these methods.
- a dermal filler can be steam sterilized (autoclaved) without degradation of physical properties, but when a dermal filler formulation contains an additional labile ingredient (such as an anti-oxidant, wrinkle reduction, haemostatic, vasoconstriction, anti-itching, anti-inflammatory, and/or anti-irritant ingredient, such as a vitamin, vitamin derivative or analgesic compound) the entire dermal filler formulation or at least the additional (heat labile) ingredient is sterilized by a non-heat treatment such as by a filtration sterilization method.
- an additional labile ingredient such as an anti-oxidant, wrinkle reduction, haemostatic, vasoconstriction, anti-itching, anti-inflammatory, and/or anti-irritant ingredient, such as a vitamin, vitamin derivative or analgesic compound
- the known dermal filler product (“Revitacare”) is sold in two separate vials or containers, one vial containing the HA (which is autoclave sterilized)) and the second vial containing any additional ingredients (the second vial contents are sterilized by filtration).
- Another known dermal filler product NCTF®135 HA is sold in a single container holding both HA and any additional ingredients, all having been sterilized by microfiltration. It is an important aspect of our invention that we mix the HA and the additional ingredients and then autoclave the completed dermal filler formulation with maintenance of gel properties (i.e. non-degraded and storage stable formulation). Additionally we have discovered dermal filler formulations that exhibit retention of stability after being treated (accelerated heat test environment) to about 45° C. for about 30 days, or at least about 60 days, or at least about 90 days with no degradation of physical properties.
- our dermal filler formulations are prepared by: (1) mixing the HA and the additional ingredient(s), and then; (2) autoclaving (no filtration sterilization of any component) the complete dermal filler formulation with; (3) maintenance of the desired gel properties (no degradation of any dermal filler constituent or ingredient, and stable).
- autoclaving means steam sterilization carried out at a temperature between about 130° C. to about 135° C. for between about one minute and about 10 minutes.
- the following tests may be performed in order to evidence or quantify cohesivity of a HA-based gel composition.
- 0.2 g or 0.4 g of a gel composition to be tested is placed in a glass syringe.
- 0.2 g or more of phosphate buffer is added to the syringe and the mixture is thoroughly mixed for about 1 hour to obtain a homogenous mixture.
- the homogenized mixture is centrifuged for 5 min at 2000 tr/min to remove the air bubbles and to allow the decantation of any particles.
- the syringe is then held in a vertical position and one drop of eosin colorant is deposited at the surface of the gel by means of a syringe and an 18G needle. After 10 min, the dye has slowly diffused through the gel.
- a relatively low cohesivity gel shows a phase separation (an upper diluted less viscous phase without particles and a lower one composed of decanted particles that are visible with the naked eye or under microscope).
- a highly cohesive gel shows substantially no phase separation, and the dye is prevented from diffusing into the cohesive formulation.
- a relatively less cohesive gel shows a clear phase separation.
- the active ingredient was incorporated into a NaHA matrix and autoclaved.
- the properties of the gel, aspect (i.e., color/clarity/homogeneity) and extrusion force were analyzed after sterilization at 3 years equivalent at room temperature. Table 1 shows that all formulations were clear, homogenous, and uncolored at the 3-year mark. The extrusion forces after autoclaving and at 3 years equivalent at room temperature are shown as well. In conclusion, the incorporation of the molecules has no impact on gel properties and ingredient structure.
- Ascorbic acid 1% w/w was incorporated into a NaHA matrix. (JUVEDERM® FORMA). The pH was adjusted to about 7 and composition was autoclaved. The gel obtained was clear, yellow and degraded.
- MAP Magnesium Ascorbyl Phosphate (0.6%, 1 or 2% w/w) was incorporated in a NaHA matrix (JUVEDERM® Ultra). The pH was adjusted to about 7 and the compositions were autoclaved. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 2. Extrusion force acceptance criteria: Conform with NaHA matrix specifications
- Rheology data of the gel containing 2% MAP after autoclaving is shown in Table 3.
- Rheological properties are followed as a function of time using a controlled stress rheometer according to the following method: frequency sweep from 0.05 to 10 Hz with 0.8% controlled strain.
- a degradation of the gel was observed by rheology.
- TAN ⁇ HZ is a rheological characterisation which shows the ratio of viscous modulus to elastic modulus. It shows the degradation of the gel.
- Tan ⁇ 1 Hz (Tan ⁇ 1 Hz formulation) ⁇ (Tan ⁇ 1 Hz NaHA matrix)
- the gels containing 0.6%, 1% and 2% were stable (pH, injection force) after autoclaving.
- Rheology data of the gels containing 0.6%, 1% and 2% w/w AA2GTM after autoclaving is shown in Table 7. No degradation of the gel was observed by rheology at each AA2GTM concentration.
- the gels containing ascorbyl glucoside maintained their properties after autoclaving and over a period of 32 days at 45° C. Surprising Rheological studies showed an increase of the stability of the gel in the presence of the additive.
- Tocopheryl Acetate (0.5% w/w) was incorporated into a NaHA matrix. (JUVEDERM® 30) and autoclaved. The gel obtained was unclear, white.
- Polyoxyethanyl- ⁇ -tocopheryl sebacate (0.7% w/w) was incorporated in a NaHA matrix (JUVEDERM® Ultra Plus) and autoclaved.
- the gel obtained was clear, but heterogenous.
- Tocopherol polyethylene glycol 1000 succinate (TPGS) was incorporated in varying concentrations (1%, 3.5% and 7% w/w) in a NAHA matrix (JUVEDERM® FORMA) and autoclaved.
- JUVEDERM® FORMA means the Juvederm formulation was used. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 9.
- Human skin fibroblasts were cultured in a 12 wells plate. At confluence, 100 ⁇ l of each compound (Juverderm® FORMA with 0.3% lidocaine, Juverderm® FORMA+AA2GTM 0.6%+Lidocaine 0.3% and Phosphate Buffer with 0.6% AA2G) was deposited in a culture insert (porosity of 0.4 ⁇ m), which was itself laid on the fibroblast monolayers. In parallel, a control without treatment was performed. Cultures were incubated for 72 hours and each experimental condition was conducted done in triplicate. At the end of incubation, cell viability was verified by microscopic observation and MTT reduction assay. Pro-collagen I secretion was measured using ELISA kit.
- Oxidation testing was used as it allows testing of the resistance of a NaHA matrix to free radicals.
- Degradation by free radicals was simulated on a rheometer (Haake Rheostress 600) by addition of 1/7 ratio of H 2 O 2 30% on the surface of a spread gel measured with a controlled stress rheometer according to the following method: frequency of 1 Hz with 0.8% controlled strain, during 3600 s at 35° C. The time value is taken at 5 Pa/s.
- Dexpanthenol was incorporated into a NaHA matrix JUVEDERM® Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 1% w/w.
- the gel was autoclaved.
- the gel obtained was clear and uncolored before and after autoclaving.
- the gel properties after autoclaving are shown in Table 13.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with a 10 ppm epinephrine bitartrate.
- the gel was autoclaved.
- the gel obtained was clear and uncolored before and after autoclaving.
- the gel (dermal filler formulation) properties after autoclaving are shown in Table 15.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with 0.3% lidocaine and 10 ppm epinephrine bitartrate. The gel was autoclaved. The gel obtained was clear and colored after autoclaving. The gel properties after autoclaving are shown in Table 16.
- the gel containing epinephrine and lidocaine was unstable.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with epinephrine bitartrate (10 ppm) and mannitol (0.9 or 4.5% w/w).
- the gels were autoclaved.
- the gel with 4.5% mannitol was clear and uncolored before and after autoclaving whereas with 0.9% mannitol was slightly colored.
- the gel properties after autoclaving is shown in Table 18.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Forma) with epinephrine bitartrate (20 ppm), lidocaine (0.3% w/w) and mannitol (4.5% w/w).
- the gel was autoclaved.
- the gel obtained was clear slightly colored after autoclaving.
- the gel properties after autoclaving are shown in Table 20.
- the gel (dermal filler formulation) was stable after 60 days at 45° C.
- Synephrine was incorporated into a NaHA matrix Juverderm Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm of synephrine.
- the gel was autoclaved.
- the gel obtained was clear and uncolored before and after autoclaving.
- the gel properties after autoclaving is shown in Table 22.
- Phenylephrine was incorporated into a matrix JUVEDERM® Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm phenylephrine.
- the gel was autoclaved.
- the gel obtained was clear and uncolored before and after autoclaving.
- the gel properties after autoclaving are shown in Table 24.
- Naphazoline was incorporated into a matrix Juverderm Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm.
- the gel was autoclaved.
- the gel obtained was clear and uncolored before and after autoclaving.
- the gel properties after autoclaving are shown in Table 26.
- a 59 year old man presents with wrinkles between his eyebrows and in the nasolabial folds. He receives injections of the dermal filler formulation of Example 11, every 3 months. A visible improvement in the wrinkles is seen.
- a 35 year old woman presents with fine lines across her forehead. She receives injections of the dermal filler formulation of Example 15, once a week for two weeks, and notices an improvement in the appearance of the skin on her forehead.
- a 35 year old man presents with a deep wrinkle across his chin and fine lines on the sides of his eyes. He receives the dermal filler formulation of Example 26 along the sides of his eyes. He receives 2 series of injections in his chin, spaced 1 week apart. The fine lines and wrinkle are visibly diminished after treatment.
- panthenol is the alcohol analog of pantothenic acid (vitamin B5), and is thus the provitamin of B5 which in vivo is oxidized to pantothenate.
- Panthenol is a highly viscous transparent liquid at room temperature, but salts of pantothenic acid (for example sodium pantothenate) are powders (typically white). Panthenol is soluble in water, alcohol and propylene glycol, soluble in ether and chloroform, and slightly soluble in glycerin.
- Panthenol has two D and L enantiomers with only the D enantiomer (D-panthenol, alos called dexpanthenol) being biologically active, however both the D and L forms have moisturizing properties.
- D-panthenol alos called dexpanthenol
- dexpanthenol alos called dexpanthenol
- panthenol has been used in the D form and as a racemic mixture of D and L (DL-panthenol).
- topical dexpanthenol cream is made by mixing with an emollient and has been used for relieving dry skin, preventing and treating sore nipples during breast-feeding, and promoting healing of burns and poorly-healing wounds.
Abstract
Description
- This application is a continuation in part of U.S. application Ser. No. 12/687,048, filed Jan. 13, 2010, the entire content of which is incorporated herein by reference.
- Skin aging is a progressive phenomenon, occurs over time and can be affected by lifestyle factors, such as alcohol consumption, tobacco and sun exposure. Aging of the facial skin can be characterized by atrophy, slackening, and fattening. Atrophy corresponds to a massive reduction of the thickness of skin tissue. Slackening of the subcutaneous tissues leads to an excess of skin and ptosis and leads to the appearance of drooping cheeks and eye lids. Fattening refers to an increase in excess weight by swelling of the bottom of the face and neck. These changes are typically associated with dryness, loss of elasticity, and rough texture.
- A variety of compounds can have an effect on the skin such as wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant effects. For example, various vitamins as well and hyaluronic acid (HA) are known to have an effect on skin. Vitamin C is the L-enantiomer of ascorbate and has a well-described role in collagen development. Vitamin C is involved in the hydroxylation of collagen, which allows it to assume its triple-helix structure. Vitamin C is also known for its antioxidant effects and is well tolerated. HA is a natural polysaccharide. It is a polymer of disaccharides that are themselves composed of D-glucuronic acid and N-acetylglucosamine, linked to one another by alternating beta-1,4 and beta-1,3 glycosidic linkages. The polymers of this recurring unit may be from 102 and 104 kilo Daltons (kDa) in size, in vivo. Hyaluronic acid represents a natural constituent of the dermis, where it plays an important role in the hydration and elasticity of skin. There is a strong correlation between the water content in the skin and levels of HA in the dermal tissue. As skin ages, the amount and quality of HA in the skin is reduced. These changes lead to drying and wrinkling of the skin.
- The use of HA in cosmetic and dermatological applications is known. HA is tolerated well and there is no immunogenicity associated with its use. The low incidence of side effects has lead to the use of HA for the treatment of wrinkles, fine lines, and scars. HA is subject to degradation through different pathways (e.g. enzymatic, temperature, free radicals), and therefore, its longevity in vivo is limited.
- Disclosures of HA, vitamin C, and C-glycosides include U.S. patent application Ser. No. 12/393,884; U.S. Pat. No. 6,921,819 (a process for cross-linking solid hyaluronic acid (HA) by reacting it with a polyfunctional linker during hydration of the HA); U.S. Pat. No. 6,685,963 (acrylic particles of HA); U.S. publication 200610194758 (a method for making a hydrogel by cross linking high and low molecular weight sodium HAs); U.S. publication 2009/0036403 (cross-linking HA with a tetra functional PEG epoxide to provide “tunably” cross-linked HA); U.S. publication 2009/0143331 (a HA dermal filler with a degradation inhibitor, such as chondroitin sulphate, in order to provide a longer lasting filler); U.S. publication 2009/0143348 (HA combined with a steroid); and U.S. publication 2009/0155314 (HA combined with a botulinum toxin). Additionally, U.S. publications 2009/0148527, 2009/0093755, and 2009/0022808 disclose HA in microspheres, cross-linked with collagen, and coated with a protein, respectively. Further disclosures of HA include: WO 2009/034559 (a process for aesthetic and/or reparative treatment of the skin with compositions that contain at least one C-glycoside derivative); WO 2009/024719 (cosmetic and pharmaceutical compositions that contain HA and a C-glycoside derivative useful for filling recesses/depressions in the skin, restore volume of the body or the face, and to reduce the sign of aging); WO 2007/128923 (a method for preparing a biocompatible gel with controlled release of one or more active lipophilic and/or amphiphilic ingredients); U.S. publication 2009/0018102 (compositions containing HA and at least one retinoid or salt/derivative thereof in combination with an oligosaccharide and a HA degradation inhibitor, to treat wrinkles, lines fibroblast depletions and scars); U.S. Pat. No. 3,763,009 (a process for improving the oxidation resistance of ascorbic acid by subjecting a mixture of ascorbic acid, maltose and/or oligosaccharides to an enzyme derived from genera Aspergillus, Penicillium or others to enzymatically convert the mixture into ascorbic acid glucoside); U.S. Pat. No. 5,616,611 (a α-Glycosyl-L-ascorbic acid that exhibits no direct reducing activity, is stable, and is useful as a stabilizer, quality-improving agent, antioxidant, physiologically active agent, a UV-absorbant in pharmaceutical and cosmetic industries); U.S. Pat. No. 5,843,907 (the production and use of a crystalline 2-O-α-D-glucopyranosyl-L-ascorbic acid suitable for vitamin C enriching agents, food stuffs, pharmaceuticals, and cosmetics); and EP 0539196 (an industrial scale preparation of high purity 2-O-α-D-glucopyranosyl-L-ascorbic acid) and US publication 2002/0151711. Commercial products incorporating HA and/or vitamin C agents include: MESOGLOW® products, REVITACARE®, and NCTF® 135/135HA Mesotherapy products. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
- Our invention includes a stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of a wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredient. Stability of the dermal filler formulation can be determined by subjecting the dermal filler formulation to a heat treatment selected from the group consisting of (a) steam sterilization (equivalently “autoclaving”) and (b) about 32 days at about 45° C., with substantial retention after the heat treatment of one or more of the dermal filler characteristics of being clear, homogenous, and cohesive, and without substantial degradation of the dermal filler formulation after the heat treatment. Preferably the steam sterilization is carried out at a temperature of at least about 120° C., as we have found that a high temperature steam sterilization reduces the sterilization time required while still providing all sterility requirements, without degradation of the dermal filler formulation occurring when the additional ingredients set forth herein are present in the formulation. More preferably, the steam sterilization is carried out at a temperature between about 130° C. and 135° C., because we found that such a particular high temperature steam sterilization not only further reduces the sterilization time required while still providing all sterility requirements but as well can be carried out with little or no degradation of the dermal filler formulation occurring. Preferably, the steam sterilization is carried out for between about one minute and about 10 minutes and more preferably for between about 1 minute and about 5 minutes.
- Our invention also includes a steam sterilization stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredients, wherein the formulation is substantially clear (i.e. little or no modification of the pre-heat [i.e. steam] treatment dermal filler formulation color occurs as compared to the color of the post heat treatment dermal filler formulation), homogenous, cohesive stable and not substantially degraded after steam sterilization. Degradation can be shown after steam sterilization by, for example, discoloration of the steam sterilized dermal filler formation and/or by a decrease in the homogeneity of the formulation or in other formulation rheological properties. Substantially clear means that on visual inspection the dermal filler formulation both before and after steam sterilization is not opaque. Substantially homogenous means the dermal filler formulation both before and after steam sterilization has the same consistency (eg well mixed throughout). Substantially monophasic means the dermal filler formulation both before and after steam sterilization comprises only one phase, meaning it is a gel with no particles. Substantially cohesive means the ability of the dermal filler formulation both before and after steam sterilization to retain its shape and resist deformation. Cohesiveness is affected by, among other factors, the molecular weight ratio of the initial free HA, the degree of crosslinking, the amount of residual free HA following crosslinking, and the ph of the dermal filler formulation. Moreover, a cohesive dermal filler formulation resists phase separation when tested according to the method disclosed by Example 1A herein.
- Our dermal filler formulations are stable after steam sterilization (i.e. at a temperature between about 120° C. to 135° C. or greater). Additionally our dermal filler formulations have long term storage or shelf life stability as shown for example by maintenance of stability of the dermal filler formulations in an environment at about 45° C. for about 32 days (accelerated heat testing), which can be considered to show that stability will be maintained for about 1 to 3 years at room temperature; stability can be determined by substantial retention at room temperature of one or more of the dermal filler characteristics of being clear, homogenous, and cohesive, and without substantial degradation of the dermal filler formulation. Stability of our dermal filler formulations can be determined over a period of or about 25 days to about 35 days at a temperature of about 35° to 50 C. Preferably, as set forth above, the accelerated heat stability testing is carried out for about 32 days at about 45° C. Substantially stable after the accelerated heat (stability) testing carried out as set forth above, or substantially stable after autoclaving or after steam sterilization of the dermal filler formulation, means the dermal filler formulation retains (as being resistant to degradation) at least 80% and preferably at least 90% and most preferably at least about 95% of at least one of its measured characteristics of transparency, pH, extrusion force, rheological characteristics, hyaluronic acid (HA) concentration, sterility, osmolarity, and same additional ingredient concentration. In our dermal filler formulation the HA is preferably cross-linked and the HA can be present in an amount of about 1 to about 40 mg/mL.
- An additional ingredient in our dermal filler formulation can be a vitamin B, C or E and the additional ingredient can be present in an amount of about 0.001% to about 10% w/w, and preferably be present in an amount of from about 0.1% to about 3% w/w. Important, the additional ingredient can provide the dermal filler formulation with improved rheological properties resulting in less extrusion force required for administration compared to an HA gel formulation without the additional constituent.
- Our invention also includes a method for treating a dermal condition such as fine lines, wrinkles, fibroblast depletions, and/or scars of a patient by administering to the patient an effective amount of a steam sterilization stable dermal filler formulation comprising a hyaluronic acid (HA) and at least one additional ingredient selected from the group consisting of wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and anti-irritant ingredients, wherein the formulation is clear, homogenous, cohesive, stable and not degraded after steam sterilization and wherein the appearance of the fine lines, wrinkles, fibroblast depletions, or scars is diminished. The administration can be by sub dermal, intra-dermal or subcutaneous injected (i.e. local injection administration) into a facial skin of the subject.
- Our invention also includes a steam sterilization stable dermal filler formulation comprising a hyaluronic acid and at least one additional ingredient selected from the group consisting of AA2G and dexpanthenol, wherein the stability of the dermal filler formulation is significantly increased by the additional ingredient—as shown by the dermal filler formulation having a Δ Tan δ 1 Hz<−0.05.
-
FIG. 1 is a representation of the structure of an ascorbyl-2-glucoside, also known as AA2G™ (Hayashibara Co., Japan). -
FIG. 2 is a graph showing the synthesis of pro-collagen (% control) for control, gel+lidocaine 0.3%, AA2G™ 0.6% in phosphate buffer, and gel+AA2G™ 0.6%+lidocaine 0.3%. -
FIG. 3 is a graph showing the extrusion force over time (3 yr equivalent at 25° C.) in compositions: control, AA2G™ plus lidocaine, and AA2G™ plus lidocaine and TPGS. -
FIG. 4 is a graph showing the pH over time (3 yr equivalent at 25° C.) in compositions: control, AA2G™ plus lidocaine, and AA2G™ plus lidocaine and TPGS. -
FIG. 5 is a graph of tan delta 1 Hz over time (3 yr equivalent at 25° C.) in compositions: control, AA2G™ plus lidocaine, and AA2G™ plus lidocaine and TPGS. -
FIG. 6 is an HPLC analysis (C18 column, eluent: sodium phosphate buffer (pH=2.2)/2-propanol 10%, 0.7 ml/min; detection at 260 nm) of AA2G™, lidocaine, and IPA (coeluent) after autoclaving (3 yr equivalent at 25° C.). -
FIG. 7 is a graph comparing antioxidant properties in compositions: control versus JUVEDERM® Ultra with lidocaine AA2G™, and JUVEDERM® Ultra with lidocaine. - Our invention is based on the discovery that a steam sterilization stable HA based dermal filler can be prepared with an additional ingredient (that is besides the HA present in the formation) which is a wrinkle reduction, antioxidant, haemostatic, vasoconstriction, anti-itching, anti-inflammatory and/or anti-irritant ingredient. An HA dermal filler within the scope of our invention (“the dermal filler formulation”) is (autoclaving) steam sterilization stable and as demonstrated stability after about 32 days at about 45° C. The formulation does not exhibit any degradation as shown by the pre and post autoclaved formulations both being clear, homogenous, and cohesive. The dermal filler formulation can also exhibit greater stability than an HA gel formulation without the additional constituent. Without wishing to be bound by theory it may be that the matrix of the cross-linked HA used in our formulation sequesters, renders non-reactive and thereby prevents the additional ingredient (as set forth for example in Examples 4-6, 10-11, 13, 15-16, 20, 24, and 25-29, supra) from degrading and causes degradation of the dermal filler formulation during steam sterilization. Additionally, the additional ingredient can be hydrophilic and provides protection to the HA from degradation during steam sterilization and/or after administration of the dermal filler formulation to a patient. Without wishing to be bound by theory, the incorporation of an additional ingredient in the dermal filler formulation may inhibit free-radical scavenging at the injection/implant site, thereby prolonging dermal filler duration after patient administration. After steam sterilization the additional ingredient can upon administration (as by subdermal injection) be released from the dermal filler formulation for cosmetic or therapeutic effect.
- Autoclave stable or steam sterilization stable as used herein means a dermal filler formulation that is resistant to degradation such that the formulation retains at least one, and preferably all, of the following aspects after steam sterilization: transparent or clear appearance pH, extrusion force and/or rheological characteristics, hyaluronic acid (HA) concentration, osmolarity, and same additional ingredient concentration.
- High molecular weight HA as used herein describes a HA material having a molecular weight of at least about 1.0 million Daltons (mw≧106 Da or 1 MDa) to about 4.0 MDa. For example, the high molecular weight HA in the present compositions may have a molecular weight of about 2.0 MDa. In another example, the high molecular weight HA may have a molecular weight of about 2.8 MDa.
- Low molecular weight HA as used herein describes a HA material having a molecular weight of less than about 1.0 MDa. Low molecular weight HA can have a molecular weight of between about 200,000 Da (0.2 MDa) to less than about 1.0 MDa, for example, between about 300,000 Da (0.3 M Da) to about 750,000 Da. (0.75 MDa).
- Degree of crosslinking as used herein refers to the intermolecular junctions joining the individual HA polymer molecules, or monomer chains, into a permanent structure, or as disclosed herein the soft tissue filler composition. Moreover, degree of crosslinking for purposes of the present disclosure is further defined as the percent weight ratio of the crosslinking agent to HA-monomeric units within the crosslinked portion of the HA based composition. It is measured by the weight ratio of HA monomers to crosslinker (HA monomers:crosslinker).
- Free HA as used herein refers to individual HA polymer molecules that are not crosslinked to, or very lightly crosslinked to (very low degree of crosslinking) the highly crosslinked (higher degree of crosslinking) macromolecular structure making up the soft tissue filler composition. Free HA generally remains water soluble. Free HA can alternatively be defined as the “uncrosslinked,” or lightly crosslinked component of the macromolecular structure making up the soft tissue filler composition disclosed herein.
- The presence of an additional ingredient in the dermal filler formulation can provide a stability and longevity that is not exhibited in a dermal filler formulation containing HA without the additional ingredient. The disclosed formulations after steam sterilization are homogenous, uncolored, clear, cohesive gel. Our invention includes methods for treating dermatological conditions, such as fine lines, wrinkles, fibroblast depletions, and/or scars afflicting a subject by administering to a patient an effective amount of a the dermal filler formulation. The patient can be any mammal, preferably a human of any age, gender or race. Although typically a subject experiencing the signs of aging skin is an adult, subjects experiencing premature aging or other skin conditions suitable for treatment (for example, a scar) with the HA gel formulation can be treated as well.
- Our dermal filler formulation comprise HA which is preferably at least partly cross-linked and can contain some not cross-linked HA. Although any pharmaceutically or cosmetically acceptable HA can be used in the disclosed compositions and formulations, in certain embodiments, the preferred HA utilized includes those sold as JUVEDERM®,
JUVEDERM® 30, JUVEDERM® Ultra Plus, JUVEDERM® Ultra injectable gel (Allergan Inc, Irvine, Calif.). In certain embodiments, the formulation comprises a HA gel matrix and an additional constituent. HA is a known hydrogel. The gel can be injectable, bioresorbable, monophasic, or biphasic. In some embodiments, the additional constituent can be directly incorporated into the HA gel. In other embodiments, in order to increase affinity with the medium or increase stability, modification of the molecule by derivatization or encapsulation of the constituent can be performed, as described above. For instance, certain oily molecules cannot be introduced directly into a hydrophilic matrix, and lead to a heterogeneous product. Derivatization of the molecule by grafting hydrophilic moieties is required to increase homogeneity of the gel. In some embodiments, the gel composition can include a biocompatible or biodegradable vessel. - The HA gel can be made by any known, suitable methods. Cross-linked HA gels typically have high viscosity and require considerable force to extrude through a fine needle. Uncross-linked HA is often used as a lubricant to facilitate the extrusion process. However, especially in HA dermal fillers and implants, uncross-linked HA does not contribute to the persistence of the final product in vivo. The formulations exhibit increased stability compared to formulations containing HA without the additional constituent. Stability is determined by assessing the homogeneity, color, and clarity, pH, and rheological properties of the gel formulation. The formulations disclosed herein are considered stable if they remain homogenous, colorless, and/or clear, and exhibit stable pH and rheology. The disclosed formulations remain stable for at least about 6 months, at least about 1 year, at least about 2 years or at least about 3 years.
- A cross-linking agent can be used to cross-link the HA according to the present disclosure. The cross-linking agent may be any agent known to be suitable for cross-linking HA and its derivatives via hydroxyl groups. Suitable cross-linking agents include but are not limited to, 1,4-butanediol diglycidyl ether, 1,4-bis(2,3-epoxypropoxy)butane, and/or 1,4-bisglycidyloxybutane (commonly known as BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene, and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane. The use of more than one cross-linking agent or a different cross-linking agent is included from the scope of the present disclosure.
- Dermal fillers can be used to treat moderate to severe facial wrinkles and folds such as nasolabial folds (those lines that extend from the nose to the corners of the mouth). In one embodiment, a dermal filler can be a gel implant formulation that includes HA and an additional constituent. The formulations disclosed herein can further include additional cosmetic agents that supplement and improve the appearance of skin. The cosmetic active ingredients may include, but are not limited to, antioxidants, vitamins, tension agents, and moisturizers.
- The formulations disclosed herein can be injected with a syringe into the mid to deep dermis of the face. The dermis is the subsurface skin layer that contains connective tissue, nerve endings, and blood vessels. The formulations, when administered as dermal fillers can improve skin appearance by lifting and adding volume to the wrinkles and folds in the treatment area. Further, in certain embodiments, improvement can be seen due to increased collagen production that results from administration of the formulation.
- As used herein, “cosmetic” is an adjective referring to improving the appearance of a surface or covering defects. Typically, cosmetic compositions can be used to improve aesthetic rather than functional aspects of a surface. Most commonly, cosmetic compositions are formulated for application as a health and beauty treatment or for affecting personal appearance of the body, for example, keratinous surfaces such as skin, hair, nails, and the like.
- As used herein, “formulation” and “composition” may be used interchangeably and refer to a combination of elements that is presented together for a given purpose. Such terms are well known to those of ordinary skill in the art.
- Examples of additional ingredients (agents) which can be included in the present dermal filler formulations are anti-itch, anti-cellulite, anti-scarring, and anti-inflammatory agents, anesthetics, anti-irritants, vasoconstrictors, vasodilators, as well as agents to prevent/stop bleeding, and improve/remove pigmentation, moisturizers, desquamating agents, tensioning agents, anti-acne agents. Anti-itch agents can include methyl sulphonyl methane, sodium bicarbonate, calamine, allantoin, kaolin, peppermint, tea tree oil, camphor, menthol, hydrocortisone and combinations thereof. Anti-cellulite agents can include forskolin, xanthine compounds such as, but not limited to, caffeine, theophylline, theobromine, and aminophylline, and combinations thereof. Anesthetic agents can include lidocaine, benzocaine, butamben, dibucaine, oxybuprocaine, pramoxine, proparacaine, proxymetacaine, tetracaine, and combinations thereof. Anti-scarring agents can include IFN-.gamma., fluorouracil, poly(lactic-co-glycolic acid), methylated polyethylene glycol, polylactic acid, polyethylene glycol and combinations thereof. Anti-inflammatory agents can include dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, cetirizine, diphenhydramine, antipyrine, methyl salicylate, loratadine, and derivatives and combinations thereof. Additionally, active agents such as epinephrine, thymidine, cytidine, uridine, antiypyrin, aminocaproic acid, tranexamic acid, eucalyptol, allantoin, glycerin, and sodium selenite, can be included. The disclosed dermal filler formulations can further comprise degradation inhibitors. Degradation inhibitors, include but are not limited to, glycosaminoglycans (e.g., heparin, heparin sulfate, dermatan sulfate, chrondroitin sulfate, o-sulfated HA, Inamarin, glucosamine, and amygdalin), antioxidants (e.g. ascorbic acid, melatonin, vitamin C, vitamin E, sodium selenite, glutathion, retinoic acid, coenzyme, beta-carotene, allopurinol, mannitol, caffeic acid, caffeine, polyphenol, theobromine, catechin), proteins (e.g., serum hyaluronidase inhibitor), and fatty acids (e.g. saturated C10 to C22 fatty acids), vitamin B and complex, and combinations thereof as noted, in certain embodiments, the additional ingredient can be an antioxidant. In certain embodiments, the antioxidant comprises a vitamin C such as ascorbyl-2-glucoside (available as AA2G™. Hayashibara Co., Japan) (
FIG. 1 ), and/or a vitamin E such as d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Anti-irritants can include thymol, bisabolol. Healing agents can include allantoin, eucalyptol, chitosane, cytidine, thimidine, uridine, lanoline. Anti-bleeding: epinephrine, norepinephrine, phenylephrine, synephrine, naphazoline, aminocaproic acid, tranexamic acid, ethamsylate, vitamin K. Collagen promoters can include retinol, peptide sequences. Additionally, active ingredients (agents) such as epinephrine, thymidine, cytidine, uridine, antiypyrine, aminocaproic acid, eucalyptol, sodium selenite, can be included. - In some embodiments, the HA is present at a concentration of about 1 to about 40 mg/mL, or about 10 to about 40 mg/mL, or about 20 to about 30 mg/mL. In certain embodiments, the HA is present in a concentration of about 20 to about 25 mg/mL. In certain embodiments, the HA is present at a concentration of 24 mg/mL. The additional constituent can be present in an amount of about 0.001 to about 10% w/w, or from about 0.001 to about 5% w/w, or from 0.3 to about 3% w/w.
- In certain embodiments, the disclosure provides a dermal filler comprising (a) about 90 wt %, or about 95 wt %, or about 100 wt % of a high molecular weight (about 1 million to about 3 million Daltons) HA; and (b) 0 wt %, or about 5 wt %, or about 10 wt % of a low molecular weight (less than 1 million Daltons) HA. In certain embodiments, the HA is present in the dermal filler at a concentration of about 10 to about 24 mg HA/mL dermal filler and the HA is about 4% to about 11% cross-linked. In certain embodiments, the cross linker is 4-butane diol diglycidyl ether (BDDE). The dermal filler can further comprise about 0.1 wt % or 0.6 wt %, or 1.0 wt % of an ascorbyl-2-glucoside, such as AA2G™ (Hayashibara, Japan). In a preferred embodiment, 0.6 wt % AA2G™ (i.e., 6 mg AA2G™/g HA) is utilized and renders a concentration of 2.1012 mM AA2G™
- Topical formulations of AA2G™ are known. However, there are no subdermally administered formulations of AA2G™ available, which is likely due to the fact that a topical AA2G™ is not thought to lend itself to an injectable formulation. The disclosure provides the first injectable formulation of AA2G™ that is efficacious, compatible, and stable over time.
- The disclosed compositions are also well suited for mesotherapy. Mesotherapy is a non-surgical cosmetic treatment technique involving intra-epidermal, intra-dermal, and/or subcutaneous injection of an agent (micronutrients, vitamins, mineral salts, etc). The compositions are administered in the form of small multiple droplets into the epidermis, dermo-epidermal junction, and/or the dermis.
- The formulations of the disclosure can be injected utilizing needles with a diameter of about 0.26 to about 0.4 mm and a length ranging from about 4 to about 14 mm. Alternately, the needles can be 21 to 32 G and have a length of about 4 mm to about 70 mm. Preferably, the needle is a single-use needle. The needle can be combined with a syringe, catheter, and/or a pistol (for example, a hydropneumatic-compression pistol).
- The formulations can be administered once or over several sessions with the subject spaced apart by a few days, or weeks. For instance, the subject can be administered a formulation every 1, 2, 3, 4, 5, 6, 7, days or every 1, 2, 3, or 4, weeks. The administration can be on a monthly or bi-monthly basis. Further, the formulation can be administered every 3, 6, 9, or 12 months.
- Our dermal filler formulation can optionally include one or more agents such as, without limitation, emulsifying agents, wetting agents, sweetening or flavoring agents, tonicity adjusters, preservatives, buffers antioxidants and flavonoids. Tonicity adjustors useful in a pharmaceutical composition of the present disclosure include, but are not limited to, salts such as sodium acetate, sodium chloride, potassium chloride, mannitol or glycerin and other pharmaceutically acceptable tonicity adjusters. Preservatives useful in the dermal filler formulation described herein include, without limitation, benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercuric acetate, and phenyl mercuric nitrate. Various buffers and means for adjusting pH can be used to prepare the dermal filler formulation, including but not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. Similarly, antioxidants useful in the dermal filler formulation include for example, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene. Flavonoids are compounds found in plants that are well known to have diverse beneficial biochemical and antioxidant effects. Subcategories of flavonoids include: flavones, flavonols, flavanonse and flavanonols. Examples of flavonoids include: luteolin, apigenin, tangeritin, quercetin, kaempferol, myricetin, fisetin, isorhamnetin, pachypodol, rhamnazin, hesperetin, naringenin, eriodictyol, homoeriodictyol, taxifolin, dihydroquercetin, dihydrokaempferol, tannic acid, tannis, condensed tannis, and hydrolysable tannis. It is understood that these and other substances known in the art can be included in the dermal filler formulations disclosed herein. The pH of the disclosed dermal filler formulations can be about 5.0 to about 8.0, or about 6.5 to about 7.5. In certain embodiments, the pH of the formulation is about 7.0 to about 7.4 or about 7.1 to about 7.3.
- A dermal filler formulation must be capable of withstanding sterilization which is a strict requirement before the product can be sold (the product must be sterile). Sterilization can be carried out by steam sterilization, filtration, microfiltration, gamma radiation, ETO light or by a combination of these methods. It is known that a dermal filler can be steam sterilized (autoclaved) without degradation of physical properties, but when a dermal filler formulation contains an additional labile ingredient (such as an anti-oxidant, wrinkle reduction, haemostatic, vasoconstriction, anti-itching, anti-inflammatory, and/or anti-irritant ingredient, such as a vitamin, vitamin derivative or analgesic compound) the entire dermal filler formulation or at least the additional (heat labile) ingredient is sterilized by a non-heat treatment such as by a filtration sterilization method. Thus, the known dermal filler product (“Revitacare”) is sold in two separate vials or containers, one vial containing the HA (which is autoclave sterilized)) and the second vial containing any additional ingredients (the second vial contents are sterilized by filtration). Another known dermal filler product NCTF®135 HA is sold in a single container holding both HA and any additional ingredients, all having been sterilized by microfiltration. It is an important aspect of our invention that we mix the HA and the additional ingredients and then autoclave the completed dermal filler formulation with maintenance of gel properties (i.e. non-degraded and storage stable formulation). Additionally we have discovered dermal filler formulations that exhibit retention of stability after being treated (accelerated heat test environment) to about 45° C. for about 30 days, or at least about 60 days, or at least about 90 days with no degradation of physical properties.
- To reiterate an important aspect of our invention and a significant distinction over known dermal fillers is that our dermal filler formulations are prepared by: (1) mixing the HA and the additional ingredient(s), and then; (2) autoclaving (no filtration sterilization of any component) the complete dermal filler formulation with; (3) maintenance of the desired gel properties (no degradation of any dermal filler constituent or ingredient, and stable).
- In the Examples below autoclaving means steam sterilization carried out at a temperature between about 130° C. to about 135° C. for between about one minute and about 10 minutes.
- For purposes of example only and not to be considered as limiting the present invention in any way, the following tests may be performed in order to evidence or quantify cohesivity of a HA-based gel composition.
- First, 0.2 g or 0.4 g of a gel composition to be tested is placed in a glass syringe. Next, 0.2 g or more of phosphate buffer is added to the syringe and the mixture is thoroughly mixed for about 1 hour to obtain a homogenous mixture. Then, the homogenized mixture is centrifuged for 5 min at 2000 tr/min to remove the air bubbles and to allow the decantation of any particles. The syringe is then held in a vertical position and one drop of eosin colorant is deposited at the surface of the gel by means of a syringe and an 18G needle. After 10 min, the dye has slowly diffused through the gel.
- After dilution of the gel, homogenization and decantation, a relatively low cohesivity gel shows a phase separation (an upper diluted less viscous phase without particles and a lower one composed of decanted particles that are visible with the naked eye or under microscope). Under the same conditions, a highly cohesive gel shows substantially no phase separation, and the dye is prevented from diffusing into the cohesive formulation. A relatively less cohesive gel, on the other hand, shows a clear phase separation.
- The active ingredient was incorporated into a NaHA matrix and autoclaved. The properties of the gel, aspect (i.e., color/clarity/homogeneity) and extrusion force were analyzed after sterilization at 3 years equivalent at room temperature. Table 1 shows that all formulations were clear, homogenous, and uncolored at the 3-year mark. The extrusion forces after autoclaving and at 3 years equivalent at room temperature are shown as well. In conclusion, the incorporation of the molecules has no impact on gel properties and ingredient structure.
-
TABLE 1 Extrusion Extrusion force (N) force (N) Content after 3 years ~ Ingredient (%) Aspect autoclaving room T° C. Allantoin 0.3 Clear PASSED PASSED 0.5 Homogeneous PASSED PASSED Cytidine 0.5 uncolored PASSED PASSED 1 PASSED PASSED Thymidine 0.5 PASSED PASSED 1 PASSED PASSED Uridine 0.5 PASSED PASSED 1 PASSED PASSED Antipyrin 0.5 PASSED PASSED 1 PASSED PASSED Aminocaproic 0.5 PASSED PASSED acid 1 PASSED PASSED Tranexamic acid 0.5 PASSED PASSED Eucalyptol 0.5 PASSED PASSED Sodium selenite 0.1 PASSED PASSED Glycerin 0.5 PASSED PASSED
Acceptance criteria: “Passed” means that the change of extrusion force (ΔF) was less than two Newtons (<2 N). In other words the measured ΔF of the extrusion force of the HA gel with the specified ingredients minus the extrusion force of the HA gel without the added ingredients was <2 N. - Ascorbic acid (1% w/w) was incorporated into a NaHA matrix. (JUVEDERM® FORMA). The pH was adjusted to about 7 and composition was autoclaved. The gel obtained was clear, yellow and degraded.
- Magnesium Ascorbyl Phosphate (MAP) (0.6%, 1 or 2% w/w) was incorporated in a NaHA matrix (JUVEDERM® Ultra). The pH was adjusted to about 7 and the compositions were autoclaved. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 2. Extrusion force acceptance criteria: Conform with NaHA matrix specifications
-
TABLE 2 After autoclaving Formulation Extrusion force (N) JUVEDERM ® Ultra + 0.6% MAP PASSED JUVEDERM ® Ultra + 1% MAP PASSED JUVEDERM ® Ultra + 2% MAP PASSED - Rheology data of the gel containing 2% MAP after autoclaving is shown in Table 3. Rheological properties are followed as a function of time using a controlled stress rheometer according to the following method: frequency sweep from 0.05 to 10 Hz with 0.8% controlled strain. A degradation of the gel was observed by rheology. TAN δ×HZ is a rheological characterisation which shows the ratio of viscous modulus to elastic modulus. It shows the degradation of the gel.
-
Δ Tan δ 1 Hz=(Tan δ 1 Hz formulation)−(Tan δ 1 Hz NaHA matrix) - Acceptance criterion: Δ Tan δ 1 Hz<0.1
-
TABLE 3 Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra + 2% MAP 0.344 - Sodium Ascorbyl Phosphate (SAP) (0.6%, 1% and 2% w/w) was incorporated in an NaHA matrix (JUVEDERM® Ultra). The pH was adjusted to about 7 and the composition was autoclaved. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 4.
-
TABLE 4 After autoclaving Formulation Extrusion force (N) JUVEDERM ® Ultra + 0.6% SAP PASSED JUVEDERM ® Ultra + 1% SAP PASSED JUVEDERM ® Ultra + 2% SAP PASSED - Rheology data of the gel containing 2% SAP after autoclaving is shown in Table 5. No degradation of the gel was observed by rheology.
-
TABLE 5 Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra + 2% SAP 0.089 - Ascorbic acid 2-Glucoside (AA2G™) at a concentration of 0.6%, 1% and 2% w/w was incorporated in an NaHA matrix (JUVEDERM® Ultra Plus). The pH was adjusted to about 7 and the composition was autoclaved. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 6.
-
TABLE 6 After autoclaving Formulation Extrusion force (N) JUVEDERM ® Ultra Plus + 0.6% AA-2G PASSED JUVEDERM ® Ultra Plus + 1% AA-2G PASSED JUVEDERM ® Ultra Plus + 2% AA-2G PASSED - The gels containing 0.6%, 1% and 2% were stable (pH, injection force) after autoclaving. Rheology data of the gels containing 0.6%, 1% and 2% w/w AA2G™ after autoclaving is shown in Table 7. No degradation of the gel was observed by rheology at each AA2G™ concentration.
-
TABLE 7 Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + 0.6% AA2G ™ −0.010 JUVEDERM ® Ultra Plus + 1% AA2G ™ −0.014 JUVEDERM ® Ultra Plus + 2% AA2G ™ −0.016 - Rheological studies showed an slightly increase of the stability of the gel in the presence of the additive.
- The shelf-life at 45° C. during 32 days was tested for the formulations prepared in example 5 and the NaHA matrix JUVEDERM® Ultra Plus. Rheology data of the gels containing 0.6%, 1% and 2% of AA2G™ are shown in Table 8.
-
TABLE 8 Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + 0.6% AA2G ™ −0.050 JUVEDERM ® Ultra Plus + 1% AA2G ™ −0.045 JUVEDERM ® Ultra Plus + 2% AA2G ™ −0.059 - The gels containing ascorbyl glucoside maintained their properties after autoclaving and over a period of 32 days at 45° C. Surprising Rheological studies showed an increase of the stability of the gel in the presence of the additive.
- Tocopheryl Acetate (0.5% w/w) was incorporated into a NaHA matrix. (JUVEDERM® 30) and autoclaved. The gel obtained was unclear, white.
- Sodium Tocopheryl Phosphate (STP), at 0.4%, 1.2% w/w, was incorporated in a NaHA matrix (JUVEDERM® FORMA) and autoclaved. The gel obtained was not clear (white).
- Polyoxyethanyl-α-tocopheryl sebacate (0.7% w/w) was incorporated in a NaHA matrix (JUVEDERM® Ultra Plus) and autoclaved. The gel obtained was clear, but heterogenous.
-
Tocopherol polyethylene glycol 1000 succinate (TPGS) was incorporated in varying concentrations (1%, 3.5% and 7% w/w) in a NAHA matrix (JUVEDERM® FORMA) and autoclaved. “JUVEDERM® FORMA” means the Juvederm formulation was used. All gels obtained were uncolored and clear. The gel properties after autoclaving are shown in Table 9. -
TABLE 9 Formulation Extrusion force (N) JUVEDERM ® FORMA + 1% TPGS PASSED JUVEDERM ® FORMA + 3.5% TPGS PASSED JUVEDERM ® FORMA + 7% TPGS PASSED - Rheology data of the gels containing 1%, 3.5% and 7% TPGS after autoclaving is shown in Table 10. No degradation of the gel was observed by rheology at each TPGS concentration.
-
TABLE 10 Formulation Δ Tan δ 1 Hz JUVEDERM ® FORMA + 1% TPGS 0.008 JUVEDERM ® FORMA + 3.5% TPGS −0.007 JUVEDERM ® FORMA + 7% TPGS −0.011 - These rheological studies showed the stability of the dermal filler formulation with a particular additional ingredient.
- The stability of various formulations was tested. The ingredients shown in Table 11 were incorporated into a NaHA matrix, and autoclaved. The degradation of the formulations after autoclaving is shows in Table 11 and after 48 days at 45° C. in Table 12. The stability of extrusion force, pH, and degradation are shown over time in
FIGS. 3 , 4, and 5, respectively. HPLC analysis (C18 column; eluent: sodium phosphate buffer (pH 2.2), 2-propanol 10%, 0.7 ml/min; detection at 260 nm) confirmed the ingredients after autoclaving and 3-year shelf-life are shown inFIG. 6 . -
TABLE 11 Δ Tan δ 1 Hz After autoclaving 45° C., 48 days JUVEDERM ® Ultra Plus + 0.059 0.020 AA2G ™ 0.6% + Lidocaine 0.3% JUVEDERM ® Ultra Plus + 0.016 0.007 AA2G ™ 0.6% + TPGS 1.5% + lidocaine 0.3% - Human skin fibroblasts were cultured in a 12 wells plate. At confluence, 100 μl of each compound (Juverderm® FORMA with 0.3% lidocaine, Juverderm® FORMA+AA2G™ 0.6%+Lidocaine 0.3% and Phosphate Buffer with 0.6% AA2G) was deposited in a culture insert (porosity of 0.4 μm), which was itself laid on the fibroblast monolayers. In parallel, a control without treatment was performed. Cultures were incubated for 72 hours and each experimental condition was conducted done in triplicate. At the end of incubation, cell viability was verified by microscopic observation and MTT reduction assay. Pro-collagen I secretion was measured using ELISA kit. The presence of 0.6% AA2G™ in a hyaluronic acid gel containing 0.3% lidocaine increased pro-collagen synthesis by a factor 3 (+292%), whereas JUVEDERM® gel with 0.3% lidocaIne showed an increase of 40% of the pro-collagen secretion (see
FIG. 2 ). - The effect of AA2G™ on NaHA oxidative degradation was studied. Oxidation testing was used as it allows testing of the resistance of a NaHA matrix to free radicals. Degradation by free radicals was simulated on a rheometer (Haake Rheostress 600) by addition of 1/7 ratio of H2O2 30% on the surface of a spread gel measured with a controlled stress rheometer according to the following method: frequency of 1 Hz with 0.8% controlled strain, during 3600 s at 35° C. The time value is taken at 5 Pa/s.
- Further, a comparison of antioxidant properties for JUVEDERM® Ultra with AA2G™ 0.6%/Lidocaine 0.3% formulation (15 800 s) versus NaHA matrix JUVEDERM® Ultra with Lidocaine (4 942 s) showed that the gel containing AA2G™ and lidocaine is more stable with respect to free radical activity (see
FIG. 7 ). AA2G™ protected against oxidative degradation by a factor of 3. - A gel containing AA2G™ at 0.6% (=6 mg/g=2.10−2 mM) was implanted in the deep dermis and subcutaneous tissues in rats. Histological evaluation at 1 week showed some mononuclear cells (lymphocytes and plasmocytes) around the implants in all implantation sites (test and control). They were also associated with macrophages. The gel containing AA2G™ appeared to be less inflammatory. The irritation index in test samples (AA2G™+NaHA) was 9.9 compared to 12.3 in controls (NaHA only). Table 12 shows the histological results at 1 week, 1 month, and 3 months. The irritation score of AA2G™ gel are (for each implantation time) lower than control (gel without AA2G™).
-
TABLE 12 NAHA + AA2G + Lido Biocompatibility ISO 10993 Cytotoxicity ✓ (non cytotoxic) Irritation ✓ (non irritant) Sensitization ✓ (non sensitizing) Implantation Test 1 week ✓ (no skin reaction) 3 weeks ✓ (no skin reaction) 3 months ✓ (no skin reaction) - Dexpanthenol was incorporated into a NaHA matrix JUVEDERM® Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 1% w/w. The gel was autoclaved. The gel obtained was clear and uncolored before and after autoclaving. The gel properties after autoclaving are shown in Table 13.
-
TABLE 13 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with PASSED 0.026 Lidocaine (0.3%) + Dexpanthenol 1% - The shelf-life at 45° C. during 30 days was tested of the formulations prepared in example 15 and the NaHA matrix JUVEDERM® Ultra Plus XC. The gel was clear, uncolored. Rheology data of the gels containing dexpanthenol 1% w/w and lidocaine 0.3% w/w are shown in Table 14.
-
TABLE 14 After 30 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with −0.071 Lidocaine (0.3%) + Dexpanthenol 1% - Rheological studies showed an increase of the stability of the gel in the presence of the additive.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with a 10 ppm epinephrine bitartrate. The gel was autoclaved. The gel obtained was clear and uncolored before and after autoclaving. The gel (dermal filler formulation) properties after autoclaving are shown in Table 15.
-
TABLE 15 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + PASSED 0.165 epinephrine bitartrate 10 ppm - Degradation of the gel was observed by rheological analysis.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with 0.3% lidocaine and 10 ppm epinephrine bitartrate. The gel was autoclaved. The gel obtained was clear and colored after autoclaving. The gel properties after autoclaving are shown in Table 16.
-
TABLE 16 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + PASSED 0.092 Lidocaine 0.3% + epinephrine bitartrate 10 ppm - A slight degradation of the gel was observed by rheological analysis.
- The shelf-life at 45° C. during 60 days was tested of the formulations prepared in Example 18 and the NaHA matrix JUVEDERM® Ultra Plus. The gel was clear, slightly colored. Rheology data of the gels containing epinephrine bitartrate (10 ppm), lidocaine (0.3% w/w) is shown in Table 17.
-
TABLE 17 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + 0.185 Lidocaine 0.3% + epinephrine bitartrate 10 ppm - After a stability of 60 days at 45° C., the gel containing epinephrine and lidocaine was unstable.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Ultra Plus) with epinephrine bitartrate (10 ppm) and mannitol (0.9 or 4.5% w/w). The gels were autoclaved. The gel with 4.5% mannitol was clear and uncolored before and after autoclaving whereas with 0.9% mannitol was slightly colored. The gel properties after autoclaving is shown in Table 18.
-
TABLE 18 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + epinephrine PASSED 0.047 bitartrate 10 ppm + mannitol 0.9% JUVEDERM ® Ultra Plus + epinephrine PASSED 0.015 bitartrate 10 ppm + mannitol 4.5% - No degradation was observed for either of the dermal filler formulations tested.
- The shelf-life at 45° C. during 60 days was tested of the formulations prepared in example 20 and the NaHA matrix JUVEDERM® Ultra Plus. The gels were clear, slightly colored. Rheology data of the gels containing epinephrine bitartrate (10 ppm) and mannitol (0.9 or 4.5% w/w) is shown in Table 19.
-
TABLE 19 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus + epinephrine 0.061 bitartrate 10 ppm + mannitol 0.9%JUVEDERM ® Ultra Plus + epinephrine 0.006 bitartrate 10 ppm + mannitol 4.5% - After a stability of days at 45° C., both gels containing epinephrine, lidocaine and manitol were stable. The composition containing 4.5% mannitol was more stable.
- Epinephrine was incorporated into a NaHA matrix (JUVEDERM® Forma) with epinephrine bitartrate (20 ppm), lidocaine (0.3% w/w) and mannitol (4.5% w/w). The gel was autoclaved. The gel obtained was clear slightly colored after autoclaving. The gel properties after autoclaving are shown in Table 20.
-
TABLE 20 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Forma + Lidocaine 0.3% + PASSED 0.026 epinephrine bitartrate 20 ppm +mannitol 4.5% - No degradation was observed.
- The shelf-life at 45° C. during 60 days was tested of the formulations prepared in example 22 and the NaHA matrix JUVEDERM® Forma. The gel was clear, slightly colored. Rheology data of the gel containing epinephrine bitartrate (20 ppm), lidocaine (0.3% w/w) and mannitol (4.5% w/w) is shown in Table 21.
-
TABLE 21 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Forma + epinephrine −0.030 bitartrate 20 ppm + mannitol 4.5% - The gel (dermal filler formulation) was stable after 60 days at 45° C.
- Synephrine was incorporated into a NaHA matrix Juverderm Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm of synephrine. The gel was autoclaved. The gel obtained was clear and uncolored before and after autoclaving. The gel properties after autoclaving is shown in Table 22.
-
TABLE 22 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® with lidocaine (0.3%) + PASSED −0.006 synephrine 100 ppm - The shelf-life at 45° C. during 60 days was tested of the formulations prepared in example 24 and the NaHA matrix JUVEDERM® Ultra Plus with Lidocaine. The gels was clear, uncolored. Rheology data of the
gel containing synephrine 100 ppm and lidocaine 0.3% w/w is shown in Table 23. -
TABLE 23 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with −0.028 lidocaine (0.3%) + synephrine 100 ppm - This rheological study showed maintenance of the stability of the gel (dermal filler formulation) in the presence of the particular additional ingredient (additive) shown.
- Phenylephrine was incorporated into a matrix JUVEDERM® Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm phenylephrine. The gel was autoclaved. The gel obtained was clear and uncolored before and after autoclaving. The gel properties after autoclaving are shown in Table 24.
-
TABLE 24 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with Lidocaine PASSED −0.002 0.3% + Phenylephrine 100 ppm - The shelf-life at 45° C. during 60 days was tested of the formulations prepared in example 26 and the NaHA matrix JUVEDERM® Ultra Plus with Lidocaine. The gel was clear, uncolored. Rheology data of the
gel containing phenylephrine 100 ppm and lidocaine 0.3% w/w are shown in Table 25. -
TABLE 25 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with Lidocaine −0.017 (0.3%) + Phenylephrine 100 ppm - This rheological study showed maintenance of the stability of the gel (dermal filler formulation) in the presence of the particular additional ingredient (additive) shown.
- Naphazoline was incorporated into a matrix Juverderm Ultra Plus with Lidocaine (with 0.3% w/w lidocaine) with a content of 100 ppm. The gel was autoclaved. The gel obtained was clear and uncolored before and after autoclaving. The gel properties after autoclaving are shown in Table 26.
-
TABLE 26 After autoclaving Extrusion Formulation force (N) Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with Lidocaine PASSED −0.003 (0.3%) + Naphazoline 100 ppm - The shelf-life at 45° C. over 60 days was tested of the formulations prepared in example 28 and the NaHA matrix JUVEDERM© Ultra Plus with Lidocaine. The gel was clear, uncolored. Rheology data of the gel containing naphazoline 100 ppm and lidocaine 0.3% w/w is shown in Table 27.
-
TABLE 27 After 60 days at 45° C. Formulation Δ Tan δ 1 Hz JUVEDERM ® Ultra Plus with Lidocaine −0.008 0.3% + Naphazoline 100 ppm - A woman, age 37, presents with fine lines around her eyes and deeper wrinkles on the sides of her mouth. She receives injections of a formulation of Example 10. She receives the injections in the fine lines and in the wrinkles once a week for 3 weeks and notices a visible improvement in the appearance of her skin.
- A 59 year old man presents with wrinkles between his eyebrows and in the nasolabial folds. He receives injections of the dermal filler formulation of Example 11, every 3 months. A visible improvement in the wrinkles is seen.
- A 35 year old woman presents with fine lines across her forehead. She receives injections of the dermal filler formulation of Example 15, once a week for two weeks, and notices an improvement in the appearance of the skin on her forehead.
- A woman, age 44, presents with uneven texture on her right cheek resulting from a loss of collagen due to aging. She receives injections of the dermal formulation of Example 20 (using the 4.5% mannitol dermal filler formulation), in her cheek to build up the areas where the collagen has been lost. A visible improvement is seen in the texture of the skin on her cheek after 3 series of injections over a 2 week period of time.
- A 35 year old man presents with a deep wrinkle across his chin and fine lines on the sides of his eyes. He receives the dermal filler formulation of Example 26 along the sides of his eyes. He receives 2 series of injections in his chin, spaced 1 week apart. The fine lines and wrinkle are visibly diminished after treatment.
- A woman, age 62, presents with wrinkles across her forehead, on the sides of her eyes, in the nasolabial folds, and a scar on her chin. She receives injections of the dermal filler formulation of Example 29 each week for one month. After the injections, the appearance of the wrinkles and the scar is visibly diminished.
- Our results above show that at least each of the two additional ingredients AA2G and dexpanthenol significantly increased the stability of the dermal filler formulation (HA gel), as shown by the dermal filler formulation having a Δ Tan δ 1 Hz<−0.05.
- With regard to dexpanthenol: panthenol is the alcohol analog of pantothenic acid (vitamin B5), and is thus the provitamin of B5 which in vivo is oxidized to pantothenate. Panthenol is a highly viscous transparent liquid at room temperature, but salts of pantothenic acid (for example sodium pantothenate) are powders (typically white). Panthenol is soluble in water, alcohol and propylene glycol, soluble in ether and chloroform, and slightly soluble in glycerin. Panthenol has two D and L enantiomers with only the D enantiomer (D-panthenol, alos called dexpanthenol) being biologically active, however both the D and L forms have moisturizing properties. For topical cosmetic use panthenol has been used in the D form and as a racemic mixture of D and L (DL-panthenol). Thus topical dexpanthenol cream (sold under the generic name “panthoderm”) is made by mixing with an emollient and has been used for relieving dry skin, preventing and treating sore nipples during breast-feeding, and promoting healing of burns and poorly-healing wounds.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
- The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
- Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
- Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
- Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of” excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein. Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
- In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described. Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term “consisting of excludes any element, step, or ingredient not specified in the claims. The transition term “consisting essentially of limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.
Claims (17)
Priority Applications (43)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/714,377 US20110172180A1 (en) | 2010-01-13 | 2010-02-26 | Heat stable hyaluronic acid compositions for dermatological use |
US12/956,542 US20110171310A1 (en) | 2010-01-13 | 2010-11-30 | Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use |
EP18206974.0A EP3511028B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
ES15178823.9T ES2613528T3 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions that include additives |
EP11709184.3A EP2523701B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
KR1020127021058A KR101768733B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
EP15178823.9A EP2959923B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
CA2786968A CA2786968C (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
PCT/IB2011/000052 WO2011086458A1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
PT117091843T PT2523701T (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
ES16191450T ES2716396T3 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions that include additives |
AU2011206389A AU2011206389B2 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
KR1020177022010A KR101830591B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
CA2905371A CA2905371C (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
ES11709184.3T ES2614434T3 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions that include additives |
EP21166261.4A EP3862029A1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
US13/005,860 US20110171311A1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
JP2012548497A JP5788412B2 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel composition containing additives |
EP16191450.2A EP3138585B1 (en) | 2010-01-13 | 2011-01-13 | Stable hydrogel compositions including additives |
KR1020207017671A KR20200078672A (en) | 2010-01-13 | 2012-01-13 | Stable Hydrogel Compositions Including Additives |
KR1020187025113A KR102127060B1 (en) | 2010-01-13 | 2012-01-13 | Stable Hydrogel Compositions Including Additives |
US13/350,518 US9114188B2 (en) | 2010-01-13 | 2012-01-13 | Stable hydrogel compositions including additives |
ES12703634T ES2805329T3 (en) | 2010-01-13 | 2012-01-13 | Stable Hydrogel Compositions Including Phenylephrine |
US13/479,551 US8946192B2 (en) | 2010-01-13 | 2012-05-24 | Heat stable hyaluronic acid compositions for dermatological use |
US13/675,993 US9333160B2 (en) | 2010-01-13 | 2012-11-13 | Heat stable hyaluronic acid compositions for dermatological use |
US14/515,799 US20150038456A1 (en) | 2010-01-13 | 2014-10-16 | Stable Hydrogel Compositions Including Additives |
US14/793,278 US20150306280A1 (en) | 2010-01-13 | 2015-07-07 | Stable hydrogel compositions including additives |
US14/797,585 US9655991B2 (en) | 2010-01-13 | 2015-07-13 | Stable hydrogel compositions including additives |
JP2015149880A JP5960894B2 (en) | 2010-01-13 | 2015-07-29 | Stable hydrogel composition containing additives |
AU2015234293A AU2015234293B2 (en) | 2010-01-13 | 2015-09-29 | Stable hydrogel compositions including additives |
US15/099,016 US9855367B2 (en) | 2010-01-13 | 2016-04-14 | Heat stable hyaluronic acid compositions for dermatological use |
JP2016124712A JP6208293B2 (en) | 2010-01-13 | 2016-06-23 | Stable hydrogel composition containing additives |
HK16107286.0A HK1219240A1 (en) | 2010-01-13 | 2016-06-23 | Stable hydrogel compositions including additives |
US15/487,767 US10449268B2 (en) | 2010-01-13 | 2017-04-14 | Stable hydrogel compositions including additives |
AU2017206247A AU2017206247B2 (en) | 2010-01-13 | 2017-07-20 | Stable hydrogel compositions including additives |
JP2017171396A JP6509979B2 (en) | 2010-01-13 | 2017-09-06 | Stable hydrogel composition containing additives |
US15/825,465 US10220113B2 (en) | 2010-01-13 | 2017-11-29 | Heat stable hyaluronic acid compositions for dermatological use |
US16/290,274 US10806821B2 (en) | 2010-01-13 | 2019-03-01 | Heat stable hyaluronic acid compositions for dermatological use |
AU2019201589A AU2019201589B2 (en) | 2010-01-13 | 2019-03-07 | Stable hydrogel compositions including additives |
JP2019071516A JP2019131586A (en) | 2010-01-13 | 2019-04-03 | Stable hydrogel compositions containing additives |
US17/064,527 US20210077658A1 (en) | 2010-01-13 | 2020-10-06 | Heat stable hyaluronic acid compositions for dermatological use |
AU2020250203A AU2020250203A1 (en) | 2010-01-13 | 2020-10-07 | Stable hydrogel compositions including additives |
US18/095,478 US20230158203A1 (en) | 2010-01-13 | 2023-01-10 | Heat stable hyaluronic acid compositions for dermatological use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/687,048 US20110171286A1 (en) | 2010-01-13 | 2010-01-13 | Hyaluronic acid compositions for dermatological use |
US12/714,377 US20110172180A1 (en) | 2010-01-13 | 2010-02-26 | Heat stable hyaluronic acid compositions for dermatological use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/687,048 Continuation-In-Part US20110171286A1 (en) | 2010-01-13 | 2010-01-13 | Hyaluronic acid compositions for dermatological use |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/956,542 Continuation-In-Part US20110171310A1 (en) | 2010-01-13 | 2010-11-30 | Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use |
US13/479,551 Division US8946192B2 (en) | 2010-01-13 | 2012-05-24 | Heat stable hyaluronic acid compositions for dermatological use |
US13/675,993 Continuation US9333160B2 (en) | 2010-01-13 | 2012-11-13 | Heat stable hyaluronic acid compositions for dermatological use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110172180A1 true US20110172180A1 (en) | 2011-07-14 |
Family
ID=44258986
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/714,377 Abandoned US20110172180A1 (en) | 2010-01-13 | 2010-02-26 | Heat stable hyaluronic acid compositions for dermatological use |
US13/479,551 Active US8946192B2 (en) | 2010-01-13 | 2012-05-24 | Heat stable hyaluronic acid compositions for dermatological use |
US13/675,993 Active 2030-03-30 US9333160B2 (en) | 2010-01-13 | 2012-11-13 | Heat stable hyaluronic acid compositions for dermatological use |
US15/099,016 Active US9855367B2 (en) | 2010-01-13 | 2016-04-14 | Heat stable hyaluronic acid compositions for dermatological use |
US15/825,465 Active US10220113B2 (en) | 2010-01-13 | 2017-11-29 | Heat stable hyaluronic acid compositions for dermatological use |
US16/290,274 Active US10806821B2 (en) | 2010-01-13 | 2019-03-01 | Heat stable hyaluronic acid compositions for dermatological use |
US17/064,527 Abandoned US20210077658A1 (en) | 2010-01-13 | 2020-10-06 | Heat stable hyaluronic acid compositions for dermatological use |
US18/095,478 Pending US20230158203A1 (en) | 2010-01-13 | 2023-01-10 | Heat stable hyaluronic acid compositions for dermatological use |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/479,551 Active US8946192B2 (en) | 2010-01-13 | 2012-05-24 | Heat stable hyaluronic acid compositions for dermatological use |
US13/675,993 Active 2030-03-30 US9333160B2 (en) | 2010-01-13 | 2012-11-13 | Heat stable hyaluronic acid compositions for dermatological use |
US15/099,016 Active US9855367B2 (en) | 2010-01-13 | 2016-04-14 | Heat stable hyaluronic acid compositions for dermatological use |
US15/825,465 Active US10220113B2 (en) | 2010-01-13 | 2017-11-29 | Heat stable hyaluronic acid compositions for dermatological use |
US16/290,274 Active US10806821B2 (en) | 2010-01-13 | 2019-03-01 | Heat stable hyaluronic acid compositions for dermatological use |
US17/064,527 Abandoned US20210077658A1 (en) | 2010-01-13 | 2020-10-06 | Heat stable hyaluronic acid compositions for dermatological use |
US18/095,478 Pending US20230158203A1 (en) | 2010-01-13 | 2023-01-10 | Heat stable hyaluronic acid compositions for dermatological use |
Country Status (1)
Country | Link |
---|---|
US (8) | US20110172180A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US8513216B2 (en) | 2007-11-30 | 2013-08-20 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US20140039061A1 (en) * | 2011-02-03 | 2014-02-06 | Q-Med Ab | Hyaluronic acid composition |
US20140088037A1 (en) * | 2012-08-29 | 2014-03-27 | Laboratoires Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
WO2014173941A2 (en) * | 2013-04-26 | 2014-10-30 | Auriga International | Method for obtaining a stable gel of hyaluronic acid and of a free form of vitamin c and/or a salt thereof |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
WO2015164533A1 (en) * | 2014-04-22 | 2015-10-29 | Allergan, Inc. | Dry dermal filler compositions and methods of reconstitution |
US20150320743A1 (en) * | 2009-05-29 | 2015-11-12 | Sylviane Villard | Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
WO2016128783A1 (en) * | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
RU2626513C2 (en) * | 2011-09-14 | 2017-07-28 | Аллерган, Инк. | Dermal filler composition for small wrinkles treating |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10201535B2 (en) | 2011-11-10 | 2019-02-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
CN114042189A (en) * | 2021-11-09 | 2022-02-15 | 无锡本物医疗器械有限公司 | Injection type filler composition and preparation method and application thereof |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
MA52880A (en) | 2018-06-15 | 2021-09-22 | Croma Pharma Ges M B H | HYDROGEL COMPOSITION CONTAINING A CROSS-LINKED POLYMER |
MX2020013006A (en) | 2018-06-15 | 2021-03-25 | Croma Pharma Gmbh | Hydrogel composition comprising a crosslinked polymer. |
IT201800007683A1 (en) * | 2018-07-31 | 2020-01-31 | Altergon Sa | Synergistic cooperative compositions useful for soft tissue augmentation, drug release and related fields |
WO2020247683A1 (en) * | 2019-06-04 | 2020-12-10 | Aquavit Pharmaceuticals, Inc. | Methods and compositions for microflillng the skin with hyaluronic acid using microchannel technology |
US20220403054A1 (en) | 2019-12-19 | 2022-12-22 | Croma-Pharma Gmbh | Thiol-modified hyaluronan and hydrogel comprising the crosslinked hyaluronan |
CN111617315B (en) * | 2020-01-14 | 2021-07-06 | 北京四环制药有限公司 | Biodegradable injection filler, preparation method and application thereof |
US11202753B1 (en) | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
Citations (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128827A (en) * | 1938-03-09 | 1938-08-30 | Frank B Killian | Method and apparatus for manufacturing thin rubber articles |
US3548056A (en) * | 1966-06-30 | 1970-12-15 | Colgate Palmolive Co | Skin protecting composition containing a water - soluble partially degraded protein |
US3763009A (en) * | 1970-10-05 | 1973-10-02 | Hayashibara Co | Synthesis process for the production of ascorbic acid glucoside |
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4060081A (en) * | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4140537A (en) * | 1975-10-22 | 1979-02-20 | Collagen Corporation | Aqueous collagen composition |
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
US4273705A (en) * | 1979-10-04 | 1981-06-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preparing collagen filaments for use in medical treatments |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4501306A (en) * | 1982-11-09 | 1985-02-26 | Collagen Corporation | Automatic syringe filling system |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US4886787A (en) * | 1984-07-23 | 1989-12-12 | Pharmacia Ab | Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said means |
US4896787A (en) * | 1987-08-14 | 1990-01-30 | Genus International | Article with resilient hinges becoming rigid under tension |
US4996787A (en) * | 1990-05-29 | 1991-03-05 | Jack N. Holcomb | SigSauer pistol with concealed radio transmitter |
US5009013A (en) * | 1988-11-30 | 1991-04-23 | Wiklund Henry W | Device in machines for the marking of workpieces |
US5084563A (en) * | 1989-10-21 | 1992-01-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline 2-O-α-D-glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5087446A (en) * | 1989-02-15 | 1992-02-11 | Chisso Corporation | Skin cosmetics |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5137723A (en) * | 1989-05-19 | 1992-08-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-Glycosyl-L-ascorbic acid, and its preparation and uses |
US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5246698A (en) * | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5252722A (en) * | 1991-10-21 | 1993-10-12 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 5-O-α-D-glucopyranosyl-L-ascorbic acid |
US5272136A (en) * | 1991-10-12 | 1993-12-21 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 5-0-α-D-Glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5278059A (en) * | 1985-12-04 | 1994-01-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaki Kenkyujo | Polypeptide possessing cyclomaltodextrin glucanotransferase activity |
US5314874A (en) * | 1991-04-19 | 1994-05-24 | Koken Co., Ltd. | Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen |
US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
US5338420A (en) * | 1992-01-30 | 1994-08-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process for preparing high α-glycosyl-L-ascorbic acid, and separation system for the process |
US5356883A (en) * | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US5428024A (en) * | 1992-02-28 | 1995-06-27 | Collagen Corporation | High concentration homogenized collagen compositions |
US5468850A (en) * | 1991-10-23 | 1995-11-21 | Kabushiki Kaisha Hayashibara | Process for preparing high 2-O-α-D-glucopyranosyl-L-ascorbic acid content product |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5571503A (en) * | 1995-08-01 | 1996-11-05 | Mausner; Jack | Anti-pollution cosmetic composition |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5616689A (en) * | 1994-07-13 | 1997-04-01 | Collagen Corporation | Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
US5633001A (en) * | 1993-03-19 | 1997-05-27 | Medinvent | Composition and a method for tissue augmentation |
US5643464A (en) * | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
US5823671A (en) * | 1994-05-10 | 1998-10-20 | Collagen Corporation | Apparatus and method of mixing materials in a sterile environment |
US5824333A (en) * | 1994-10-18 | 1998-10-20 | Ethicon, Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
US5827529A (en) * | 1991-03-30 | 1998-10-27 | Teikoku Seiyaku Kabushiki Kaisha | External preparation for application to the skin containing lidocaine |
US5880107A (en) * | 1995-12-22 | 1999-03-09 | Chemedica S.A. | Sodium hyaluronate based ophthalmic formulation for use in eye surgery |
US5935164A (en) * | 1997-02-25 | 1999-08-10 | Pmt Corporaton | Laminated prosthesis and method of manufacture |
US5980930A (en) * | 1993-01-20 | 1999-11-09 | Bristol-Myers Squibb Company | Fibres |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6224857B1 (en) * | 1996-10-17 | 2001-05-01 | Fidia, S.P.A. | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
US6335035B1 (en) * | 1995-09-29 | 2002-01-01 | L.A.M. Pharmaceutical Corporation | Sustained release delivery system |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6383219B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Implant for deep sclerectomy |
US6383218B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Sclero-ceratectomy implant for descemet's membrane |
US6418934B1 (en) * | 2000-04-19 | 2002-07-16 | Sae-Hoon Chin | Use of polymeric materials for enlarging human glans and method of performing a surgery for enlarging a human glans with the said materials |
US20020151711A1 (en) * | 1998-05-29 | 2002-10-17 | Pe Corporation (Ny) | Nucleotide compounds including a rigid linker |
US6521223B1 (en) * | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6544503B1 (en) * | 1995-06-06 | 2003-04-08 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US6627620B1 (en) * | 1998-12-18 | 2003-09-30 | Per Julius Nielsen | Composition set and kit for use in intraocular surgery |
US6630486B1 (en) * | 1997-09-22 | 2003-10-07 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US6685963B1 (en) * | 1998-07-01 | 2004-02-03 | Corneal Industrie | Diphasic injection composition containing dispersed and continuous phases useful for reparative and plastic surgery |
US6716251B1 (en) * | 1997-06-13 | 2004-04-06 | Aventis Pharmaceuticals Holdings, Inc. | Implant for subcutaneous or intradermal injection |
US6767924B2 (en) * | 1986-12-23 | 2004-07-27 | Tristrata Technology, Inc. | Method of using hydroxycarboxylic acids or related compounds for treating skin changes associated with intrinsic and extrinsic aging |
US6767928B1 (en) * | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
US6893466B2 (en) * | 2000-08-30 | 2005-05-17 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
US6921819B2 (en) * | 2000-07-19 | 2005-07-26 | Laboratoires D'esthetique Appliquee | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
US6939562B2 (en) * | 2000-08-30 | 2005-09-06 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
US6979440B2 (en) * | 2001-01-29 | 2005-12-27 | Salvona, Llc | Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric |
US20060040894A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid |
US20060174758A1 (en) * | 2003-03-19 | 2006-08-10 | Josef Beck | Pressure pin and axial piston machine having said pressure pin |
US20060194758A1 (en) * | 2003-04-10 | 2006-08-31 | Pierre Lebreton | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained |
US7119062B1 (en) * | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
US7166570B2 (en) * | 2003-11-10 | 2007-01-23 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US7314636B2 (en) * | 2001-06-29 | 2008-01-01 | Medgraft Microtech, Inc. | Biodegradable injectable implants containing glycolic acid |
US20080268547A1 (en) * | 2004-04-09 | 2008-10-30 | Board Of Regents, The University Of Texas System | Systems and Methods for Indicating Oxidation of Consumer Products |
US20090018102A1 (en) * | 2005-12-21 | 2009-01-15 | Galderma Research & Development | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith |
US20090022808A1 (en) * | 2007-05-23 | 2009-01-22 | Allergan, Inc. | Coated Hyaluronic Acid Particles |
US20090036403A1 (en) * | 2007-07-30 | 2009-02-05 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US20090093755A1 (en) * | 2007-10-09 | 2009-04-09 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US20090143331A1 (en) * | 2007-11-30 | 2009-06-04 | Dimitrios Stroumpoulis | Polysaccharide gel formulation having increased longevity |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20090155314A1 (en) * | 2007-12-12 | 2009-06-18 | Ahmet Tezel | Dermal filler |
US7902171B2 (en) * | 2004-01-14 | 2011-03-08 | Reinmueller Johannes | Composition for treating inflammatory diseases |
Family Cites Families (280)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA949965A (en) | 1971-12-03 | 1974-06-25 | Robert H. Marchessault | Method of preparing cross-linked starch and starch derivatives |
JPS581933Y2 (en) | 1979-04-23 | 1983-01-13 | 株式会社日本製鋼所 | Cable clamp device |
JPS55153711A (en) | 1979-05-19 | 1980-11-29 | Pola Chem Ind Inc | Cosmetic lotion |
IT1229075B (en) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Topical compsn. contg. hyaluronic acid deriv. as vehicle |
GB8418772D0 (en) | 1984-07-24 | 1984-08-30 | Geistlich Soehne Ag | Chemical substances |
SE8501022L (en) | 1985-03-01 | 1986-09-02 | Pharmacia Ab | FORMAT CREATES AND PROCEDURES FOR ITS PREPARATION |
FR2608456B1 (en) | 1986-12-18 | 1993-06-18 | Mero Rousselot Satia | MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM |
US5017229A (en) | 1990-06-25 | 1991-05-21 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
US6174999B1 (en) | 1987-09-18 | 2001-01-16 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
IT1219587B (en) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES |
JPH02153711A (en) | 1988-12-05 | 1990-06-13 | Honda Motor Co Ltd | Method and mold for molding instrument panel |
EP0416250A3 (en) | 1989-08-01 | 1991-08-28 | The Research Foundation Of State University Of New York | N-acylurea and o-acylisourea derivatives of hyaluronic acid |
CA2023922A1 (en) | 1989-09-05 | 1991-03-06 | James M. Curtis | Method of manufacturing an implantable article provided with a micropillared surface |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
IT1260154B (en) | 1992-07-03 | 1996-03-28 | Lanfranco Callegaro | HYALURONIC ACID AND ITS DERIVATIVES IN INTERPENETRATING POLYMERS (IPN) |
JP3290490B2 (en) | 1993-01-25 | 2002-06-10 | 株式会社林原生物化学研究所 | Metal salt of ascorbic acid-2-O-α-glucoside and pharmaceutical use thereof |
EP0692975A4 (en) | 1993-04-08 | 2000-11-29 | Univ Queensland | Administration of vaso-active agent and therapeutic agent |
US20050186673A1 (en) | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
FR2733427B1 (en) | 1995-04-25 | 2001-05-25 | W K Et Associes | INJECTABLE BIPHASIC COMPOSITIONS CONTAINING HYALURONIC ACID, ESPECIALLY USEFUL IN REPAIRING AND AESTHETIC SURGERIES |
FR2733426B1 (en) | 1995-04-25 | 1997-07-18 | Debacker Yves | MEDICAL DEVICE FOR FILLING SKIN VOLUME DEFORMATIONS SUCH AS WRINKLES AND SCARS BY INJECTION OF 2 DIFFERENT PHYSICO-CHEMICAL FORMS OF A BIOLOGICAL POLYMER |
US5643586A (en) | 1995-04-27 | 1997-07-01 | Perricone; Nicholas V. | Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
CA2154979A1 (en) | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
US5980948A (en) | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
FR2752843B1 (en) | 1996-08-30 | 1998-10-16 | Sod Conseils Rech Applic | CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS |
US5866165A (en) | 1997-01-15 | 1999-02-02 | Orquest, Inc. | Collagen-polysaccharide matrix for bone and cartilage repair |
US7767452B2 (en) | 1997-02-20 | 2010-08-03 | Kleinsek Don A | Tissue treatments with adipocyte cells |
CN1235617C (en) | 1998-03-31 | 2006-01-11 | 玫琳凯有限公司 | Skin lightening composition containing magnesium ascorbyl phosphate and uniontan-U34 TM (extract formulation of cucumber extract and lemon extract) |
JP4981198B2 (en) | 1998-03-31 | 2012-07-18 | 格 山本 | Acylated derivatives of glycosyl-L-ascorbic acid |
ITPD980169A1 (en) | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | AMIDES OF HYALURONIC ACID AND ITS DERIVATIVES AND PROCESS FOR THEIR PREPARATION. |
IT1301994B1 (en) | 1998-08-05 | 2000-07-20 | Jasper Ltd Liability Co | HYALURONIC ACID DERIVATIVES. |
US6630457B1 (en) | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
IT1303738B1 (en) | 1998-11-11 | 2001-02-23 | Aquisitio S P A | CARBOXYLATE POLYSACCHARIDE CROSS-LINKING PROCESS. |
GB9902652D0 (en) | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
CA2299692C (en) | 1999-03-01 | 2007-09-18 | Johnson & Johnson Vision Care, Inc. | Method of sterilization |
US6444647B1 (en) | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US7015198B1 (en) | 1999-05-11 | 2006-03-21 | Orentreich Foundation For The Advancement Of Science, Inc. | Materials for soft tissue augmentation and methods of making and using same |
JP3476130B2 (en) | 1999-12-17 | 2003-12-10 | 西川ゴム工業株式会社 | Food formulation and food manufacturing |
JP2001192336A (en) | 2000-01-11 | 2001-07-17 | Hironori Yamamoto | Endoscopic demucosation using highly viscous substance |
US6682760B2 (en) | 2000-04-18 | 2004-01-27 | Colbar R&D Ltd. | Cross-linked collagen matrices and methods for their preparation |
EP1162205B1 (en) | 2000-06-08 | 2003-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process for producing 2-O-Alpha-D-Glucopyranosyl-L-ascorbic acid in high content |
US6991652B2 (en) | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
EP1294414B1 (en) | 2000-06-29 | 2006-03-15 | Biosyntech Canada Inc. | Composition and method for the repair and regeneration of cartilage and other tissues |
FR2811671B1 (en) | 2000-07-17 | 2003-02-28 | Corneal Ind | POLYMER (S) HYDROGEL, BIODEGRATION RESISTANT, PREPARATION AND USE AS TISSUE REGENERATION SUPPORT |
WO2002009792A1 (en) | 2000-07-28 | 2002-02-07 | Anika Therapeutics, Inc. | Bioabsorbable composites of derivatized hyaluronic acid |
JP4187917B2 (en) | 2000-09-08 | 2008-11-26 | 独立行政法人科学技術振興機構 | Method for producing glycosaminoglycan-collagen complex for tissue regeneration matrix |
AU2001294459A1 (en) | 2000-10-06 | 2002-04-15 | Jagotec Ag | A controlled-release, parenterally administrable microparticle preparation |
KR100375299B1 (en) | 2000-10-10 | 2003-03-10 | 주식회사 엘지생명과학 | Crosslinked derivatives of hyaluronic acid by amide formation and their preparation methods |
WO2003053325A2 (en) | 2000-12-13 | 2003-07-03 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
AUPR289601A0 (en) | 2001-02-05 | 2001-03-01 | Commonwealth Scientific And Industrial Research Organisation | Method of tissue repair |
TW574301B (en) | 2001-05-02 | 2004-02-01 | Ind Tech Res Inst | Manufacturing method of epoxide crosslinked polysaccharides matrix |
US20050227936A1 (en) | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA) |
US6749841B2 (en) | 2001-07-26 | 2004-06-15 | Revlon Consumer Products Corporation | Stabilized aqueous acidic antiperspirant compositions and related methods |
JP4230135B2 (en) | 2001-08-21 | 2009-02-25 | 独立行政法人科学技術振興機構 | Method for producing glycosaminoglycan-collagen complex cross-linked by multifunctional cross-linking agent |
WO2003041723A1 (en) | 2001-11-12 | 2003-05-22 | Reinmueller Johannes | Pharmaceutical applications of hyaluronic acid preparations |
US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
WO2003057707A1 (en) | 2001-12-28 | 2003-07-17 | Suntory Limited | 2-o-( -d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
US20060189516A1 (en) | 2002-02-19 | 2006-08-24 | Industrial Technology Research Institute | Method for producing cross-linked hyaluronic acid-protein bio-composites |
US7303814B2 (en) | 2002-02-21 | 2007-12-04 | Encelle, Inc. | Immobilized bioactive hydrogel matrices as surface coatings |
JP3916516B2 (en) | 2002-06-10 | 2007-05-16 | 独立行政法人科学技術振興機構 | Scaffolding material for hard tissue-soft tissue interface regeneration |
US6780366B2 (en) | 2002-08-15 | 2004-08-24 | Mentor Corporation | Drip retainer |
KR100523953B1 (en) | 2002-08-27 | 2005-10-25 | 주식회사 엘지생명과학 | Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same |
KR100507545B1 (en) | 2002-09-03 | 2005-08-09 | 주식회사 엘지생명과학 | Hyaluronic acid derivatives and processes for preparing them |
US20040127932A1 (en) | 2002-09-12 | 2004-07-01 | Shah Tilak M. | Dip-molded polymeric medical devices with reverse thickness gradient, and method of making same |
CA2516547A1 (en) | 2002-09-30 | 2004-04-15 | Alza Corporation | Drug delivery device having coated microprojections incorporating vasoconstrictors |
DE10246340A1 (en) | 2002-10-04 | 2004-04-29 | Wohlrab, David, Dr. | Combination preparation of hyaluronic acid and at least one local anesthetic and its use |
US20040101959A1 (en) | 2002-11-21 | 2004-05-27 | Olga Marko | Treatment of tissue with undifferentiated mesenchymal cells |
EP1581270A2 (en) | 2002-12-30 | 2005-10-05 | Angiotech International Ag | Silk-containing stent graft |
TWI251596B (en) | 2002-12-31 | 2006-03-21 | Ind Tech Res Inst | Method for producing a double-crosslinked hyaluronate material |
EP1592715A1 (en) | 2003-01-31 | 2005-11-09 | Biosphere S.p.A. | Water soluble and biocompatible gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters |
WO2004073759A1 (en) | 2003-02-19 | 2004-09-02 | Aventis Pharmaceuticals Holdings Inc. | Composition and method for intradermal soft tissue augmentation |
JP2006521180A (en) | 2003-03-25 | 2006-09-21 | バイオキュア・インコーポレーテッド | Medical device with hydrogel yarn |
AU2003901834A0 (en) | 2003-04-17 | 2003-05-01 | Clearcoll Pty Ltd | Cross-linked polysaccharide compositions |
JP2004323453A (en) | 2003-04-25 | 2004-11-18 | Chisso Corp | Decomposable gel and method for producing the same |
CN100352031C (en) | 2003-05-13 | 2007-11-28 | 三益半导体工业株式会社 | Wafer demounting method, wafer demounting device, and wafer demounting and transferring machine |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
TWI329024B (en) | 2003-06-26 | 2010-08-21 | Suntory Holdings Ltd | Composition for skin, kit for skin and skin permeation enhancer |
CA2534033A1 (en) | 2003-07-30 | 2005-02-10 | Anteis S.A. | Complex matrix for biomedical use |
EP1658009B1 (en) | 2003-08-20 | 2011-10-12 | Philips Intellectual Property & Standards GmbH | Method and device for flow reconstruction |
US8153591B2 (en) | 2003-08-26 | 2012-04-10 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
AU2004285480B2 (en) | 2003-10-22 | 2010-12-16 | Encelle, Inc. | Bioactive hydrogel compositions for regenerating connective tissue |
CN1897898A (en) | 2003-10-24 | 2007-01-17 | 阿尔扎公司 | Pretreatment method and system for enhancing transdermal drug delivery |
ES2406555T3 (en) | 2003-10-29 | 2013-06-07 | Teijin Limited | Composed of hyaluronic acid, hydrogel thereof and material to treat joints |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
WO2005051451A2 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
EP1535952B1 (en) | 2003-11-28 | 2013-01-16 | Universite Louis Pasteur | Method for preparing crosslinked polyelectrolyte multilayer films |
US8124120B2 (en) | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US8524213B2 (en) | 2003-12-30 | 2013-09-03 | Genzyme Corporation | Polymeric materials, their preparation and use |
WO2005066215A1 (en) | 2003-12-30 | 2005-07-21 | Genzyme Corporation | Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
CA2536096A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
FR2865737B1 (en) | 2004-02-03 | 2006-03-31 | Anteis Sa | BIOCOMPATIBLE RETICLE GEL |
US20050226936A1 (en) | 2004-04-08 | 2005-10-13 | Q-Med Ab | Method of soft tissue augmentation |
US7654997B2 (en) | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
US8288362B2 (en) | 2004-05-07 | 2012-10-16 | S.K. Pharmaceuticals, Inc. | Stabilized glycosaminoglycan preparations and related methods |
EP1750769B1 (en) | 2004-05-20 | 2013-01-23 | Mentor Worldwide LLC | Methods for making injectable polymer hydrogels |
ES2609105T3 (en) | 2004-05-20 | 2017-04-18 | Mentor Worldwide Llc | Covalent linking method of hyaluronic acid and chitosan |
CN101027065A (en) | 2004-06-15 | 2007-08-29 | 陈献 | Phospholipid compositions and methods for their preparation and use |
FR2873379B1 (en) | 2004-07-23 | 2008-05-16 | Jerome Asius | PROCESS FOR THE PREPARATION OF RETICULATED HYALURONIC ACID, RETICULATED HYALURONIC ACID WHICH CAN BE OBTAINED BY THIS METHOD, IMPLANT CONTAINING THE RETICULATED HYALURONIC ACID, AND USE THEREOF |
WO2006015490A1 (en) | 2004-08-13 | 2006-02-16 | Ottawa Health Research Institute | Ophthalmic devices and related methods and compositions |
US20060040895A1 (en) | 2004-08-19 | 2006-02-23 | Kipling Thacker | Aesthetic use of hyaluronan |
US7288263B2 (en) | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
US7414021B2 (en) | 2004-10-01 | 2008-08-19 | Vincent Carmine Giampapa | Method and composition for restoration of age related tissue loss in the face or selected areas of the body |
KR100762928B1 (en) | 2004-10-29 | 2007-10-04 | 재단법인서울대학교산학협력재단 | Nonwoven Nanofibrous Membranes of Silk Fibroin for Guided Bone Tissue Regeneration and Their Preparation Method |
NO20044818D0 (en) | 2004-11-05 | 2004-11-05 | Bioforsk As | Spermine in cosmetic preparations |
US20060105022A1 (en) | 2004-11-15 | 2006-05-18 | Shiseido Co., Ltd. | Process for preparing crosslinked hyaluronic acid gel |
DK1817347T3 (en) | 2004-11-24 | 2017-08-14 | Albumedix As | Process for Crosslinking Hyaluronic Acid with Divinyl Sulfone |
FR2878444B1 (en) | 2004-11-30 | 2008-04-25 | Corneal Ind Soc Par Actions Si | VISCOELASTIC SOLUTIONS COMPRISING SODIUM HYALURONATE AND HYDROXYPROPYLMETHYLCELLULOSE, PREPARATION AND USES |
WO2006067608A1 (en) | 2004-12-22 | 2006-06-29 | Laboratoire Medidom S.A. | Aqueous formulations based on sodium hyaluronate for parenteral use |
US8265758B2 (en) | 2005-03-24 | 2012-09-11 | Metacure Limited | Wireless leads for gastrointestinal tract applications |
US7899540B2 (en) | 2005-04-29 | 2011-03-01 | Cyberonics, Inc. | Noninvasively adjustable gastric band |
US20060257488A1 (en) | 2005-05-10 | 2006-11-16 | Cytophil, Inc. | Injectable hydrogels and methods of making and using same |
EP1726299A3 (en) | 2005-05-27 | 2007-04-18 | StratoSphere Pharma AB | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture |
AU2006255097B2 (en) | 2005-06-06 | 2012-02-09 | Georgetown University | Compositions and methods for lipo modeling |
US7491709B2 (en) | 2005-07-01 | 2009-02-17 | Wayne Carey | Treatment with hyaluronic acid |
CN102266274B (en) | 2005-08-11 | 2016-05-18 | 株式会社林原 | Agent for enhancing collagen production and uses thereof |
JP4982718B2 (en) | 2005-08-31 | 2012-07-25 | 株式会社林原 | Composition for oral intake for beautiful skin |
EP1940468B1 (en) * | 2005-09-07 | 2017-11-15 | AMO Regional Holdings | Bi-modal hyaluronate solution |
JP4856920B2 (en) | 2005-09-22 | 2012-01-18 | 高周波熱錬株式会社 | Crushing method and crushing tool |
EP3015101B1 (en) | 2005-10-03 | 2019-08-21 | PINSKY, Mark A. | Non-phospholipid liposomes comprising hyaluronic acid |
US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
US20070104692A1 (en) | 2005-11-07 | 2007-05-10 | Quijano Rodolfo C | Breast tissue regeneration |
US20070104693A1 (en) | 2005-11-07 | 2007-05-10 | Quijano Rodolfo C | Breast augmentation system |
EP1968499A1 (en) | 2005-12-14 | 2008-09-17 | Anika Therapeutics Inc. | Bioabsorbable implant of hyaluronic acid derivative for treatment of osteochondral and chondral defects |
US20070203095A1 (en) | 2005-12-14 | 2007-08-30 | Anika Therapeutics, Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
FR2895907B1 (en) | 2006-01-06 | 2012-06-01 | Anteis Sa | VISCOELASTIC GEL FOR DERMATOLOGICAL USE |
US20070184087A1 (en) | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
US20070212385A1 (en) | 2006-03-13 | 2007-09-13 | David Nathaniel E | Fluidic Tissue Augmentation Compositions and Methods |
CA2645324A1 (en) | 2006-03-15 | 2007-09-27 | Surmodics, Inc. | Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof |
US8152710B2 (en) | 2006-04-06 | 2012-04-10 | Ethicon Endo-Surgery, Inc. | Physiological parameter analysis for an implantable restriction device and a data logger |
FR2900575B1 (en) | 2006-05-05 | 2008-10-17 | Anteis Sa | BIOCOMPATIBLE CONTROLLED RELEASE GEL, PREPARATION METHOD AND USE THEREOF |
EP2019647A4 (en) | 2006-05-19 | 2010-04-28 | Univ Boston | Novel hydrophilic polymers as medical lubricants and gels |
US20070298005A1 (en) | 2006-06-22 | 2007-12-27 | Marie-Josee Thibault | Injectable composition for treatment of skin defects or deformations |
WO2008003321A2 (en) | 2006-07-07 | 2008-01-10 | Novozymes Biopolymer A/S | Compositions with several hyaluronic acid fractions for cosmetic use |
US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
AR062046A1 (en) | 2006-07-25 | 2008-08-10 | Osmotica Pharmaceutical Argentina S A | OPHTHALMIC SOLUTIONS |
EP1884231A1 (en) | 2006-08-01 | 2008-02-06 | Auriga International S.A. | Cosmetic or pharmaceutical composition containing hyaluronic acid |
DE102006038629A1 (en) | 2006-08-17 | 2008-02-21 | Dr. Suwelack Skin & Health Care Ag | Stabilized active ingredient composition |
ITMI20061726A1 (en) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | CROSSLINKATI DERIVATIVES BASED ON HYALURONIC ACID RETICULATED VIA CLICK CHEMISTRY |
US20100035838A1 (en) | 2006-09-19 | 2010-02-11 | Geoffrey Kenneth Heber | Cross-linked polysaccharide gels |
US8968272B2 (en) | 2006-10-06 | 2015-03-03 | Lipocosm Llc | Closed system and method for atraumatic, low pressure, continuous harvesting, processing, and grafting of lipoaspirate |
FR2908415B1 (en) | 2006-11-10 | 2009-01-23 | Abr Dev Sarl | RETICULATED HYALURONIC ACID AND PROCESS FOR PREPARING THE SAME |
WO2008063569A1 (en) | 2006-11-16 | 2008-05-29 | Coapt Systems, Inc. | Co-mixed human fat and gel suspension implant material |
WO2008066297A1 (en) | 2006-11-27 | 2008-06-05 | Mazence Inc. | Pharmaceutical composition for treatment and prevention of restenosis |
FR2909560B1 (en) | 2006-12-06 | 2012-12-28 | Fabre Pierre Dermo Cosmetique | HYALURONIC ACID GEL FOR INTRADERMAL INJECTION |
CA2672495C (en) | 2006-12-11 | 2017-01-17 | Chi2Gel Ltd. | Novel injectable chitosan mixtures forming hydrogels |
KR100759091B1 (en) | 2006-12-13 | 2007-09-17 | 조강선 | Dermal filler composition |
DK2107913T3 (en) | 2006-12-22 | 2012-05-21 | Croma Pharma Ges M B H | Use of thiolated polysaccharides for tissue building |
US20080188416A1 (en) | 2007-02-05 | 2008-08-07 | Freedom-2, Inc. | Tissue fillers and methods of using the same |
CA2677498C (en) | 2007-02-05 | 2016-05-17 | Carbylan Biosurgery, Inc. | Polymer formulations for delivery of bioactive agents |
US7776840B2 (en) | 2007-02-21 | 2010-08-17 | Cutanea Life Sciences, Inc. | Methods of use of biomaterial and injectable implant containing biomaterial |
US7939578B2 (en) | 2007-02-23 | 2011-05-10 | 3M Innovative Properties Company | Polymeric fibers and methods of making |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
EP2155149A2 (en) | 2007-05-11 | 2010-02-24 | Galderma Research & Development | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
US20100323985A1 (en) | 2007-05-11 | 2010-12-23 | Marc Moutet | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
EP2155154A2 (en) | 2007-05-11 | 2010-02-24 | Galderma Research & Development | Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
CA2687990A1 (en) | 2007-05-23 | 2008-12-04 | Allergan, Inc. | Cross-linked collagen and uses thereof |
WO2008148071A2 (en) | 2007-05-24 | 2008-12-04 | Nidus2, Llc | Injectable dermis |
EP2201910B1 (en) | 2007-06-01 | 2013-04-03 | Allergan, Inc. | Biological tissue growth support trough induced tensile stress |
WO2008157608A1 (en) | 2007-06-18 | 2008-12-24 | Cartlix, Inc. | Composite scaffolds for tissue regeneration |
WO2009005790A2 (en) | 2007-06-29 | 2009-01-08 | Carbylan Biosurgery, Inc. | Sterile thiol-derivatized hyaluronic acid polymer compositions and uses thereof |
EP2520309A1 (en) | 2007-07-27 | 2012-11-07 | Humacyte, Inc. | Compositions and methods for soft tissue augmentation |
US20090060852A1 (en) | 2007-07-27 | 2009-03-05 | Jack Dejovin | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging |
US20120071437A1 (en) | 2007-07-30 | 2012-03-22 | Allergan, Inc. | Tunable crosslinked polysaccharide compositions |
US20110077737A1 (en) | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
FR2920000B1 (en) | 2007-08-13 | 2010-01-29 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIC ACID, AND COSMETIC PROCESS FOR DECREASING SIGNS OF AGING |
AU2008289178A1 (en) | 2007-08-16 | 2009-02-26 | Carnegie Mellon University | Inflammation-regulating compositions and methods |
EP2033689A1 (en) | 2007-08-22 | 2009-03-11 | Italfarmacia S.r.l. | Injectable dermatological composition for treatment of the wrinkles |
EP2185596B1 (en) | 2007-08-24 | 2018-06-13 | Eastman Chemical Company | Mixed cellulose esters having low bifringence and films made therefrom |
KR100813224B1 (en) | 2007-08-24 | 2008-03-13 | 한양대학교 산학협력단 | Thermo-reversible coacervate combination gels for protein delivery |
FR2920968B1 (en) | 2007-09-14 | 2009-11-13 | Oreal | COSMETIC PROCESS FOR AESTHETIC TREATMENT AND / OR REPAIR OF SKIN |
US7910134B2 (en) | 2007-10-29 | 2011-03-22 | Ayman Boutros | Alloplastic injectable dermal filler and methods of use thereof |
EP3498299A1 (en) | 2007-11-16 | 2019-06-19 | Aclaris Therapeutics, Inc. | Compositions and methods for treating purpura |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
FR2924615B1 (en) | 2007-12-07 | 2010-01-22 | Vivacy Lab | HYDROGEL COHESIVE BIODEGRADABLE. |
US20090181104A1 (en) | 2007-12-14 | 2009-07-16 | Gino Rigotti | Breast reconstruction or augmentation using computer-modeled deposition of processed adipose tissue |
CA2706183A1 (en) | 2007-12-21 | 2009-07-02 | Encecor Ab | Cross-linked hydrogel containing an active substance |
TW200927074A (en) | 2007-12-25 | 2009-07-01 | Univ Nat Taiwan | Colloidal frame used in tissue engineering |
US20090169615A1 (en) | 2007-12-26 | 2009-07-02 | Pinsky Mark A | Collagen Formulations for Improved Skin Care |
US20090192541A1 (en) | 2008-01-28 | 2009-07-30 | Ethicon Endo-Surgery, Inc. | Methods and devices for predicting performance of a gastric restriction system |
US8337389B2 (en) | 2008-01-28 | 2012-12-25 | Ethicon Endo-Surgery, Inc. | Methods and devices for diagnosing performance of a gastric restriction system |
BRPI0908087A2 (en) | 2008-02-11 | 2015-08-25 | Univ Johns Hopkins | Compositions and Methods for Adipose Tissue Implantation and Adipose Tissue Products |
US20090291986A1 (en) | 2008-05-22 | 2009-11-26 | Apostolos Pappas | Composition and method of treating facial skin defect |
US20090297632A1 (en) | 2008-06-02 | 2009-12-03 | Waugh Jacob M | Device, Methods and Compositions to Alter Light Interplay with Skin |
DE102009055227B3 (en) | 2009-12-23 | 2011-06-22 | Human Med AG, 19061 | Method for conveying a fluid and device for generating a volume flow |
DE102008027486B4 (en) | 2008-06-10 | 2013-11-07 | Human Med Ag | Method and apparatus for separating tissue cells from a fluid |
HUE043642T2 (en) | 2008-07-02 | 2019-08-28 | Allergan Inc | Compositions for soft tissue filling and regeneration |
WO2010003797A1 (en) | 2008-07-09 | 2010-01-14 | Novozymes Biopharma Dk A/S | Hyaluronic acid for corneal wound healing |
US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
EP3184552B1 (en) | 2008-09-02 | 2020-08-12 | Tautona Group LP | Threads of hyaluronic acid, methods of making thereof and uses thereof |
EP2341953B1 (en) | 2008-09-04 | 2018-11-21 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
FI20085839A0 (en) | 2008-09-08 | 2008-09-08 | Timo Ylikomi | Methods and tools for soft tissue technology |
GB0816496D0 (en) | 2008-09-10 | 2008-10-15 | Zhao Xiaobin | Hyaluronic acid cryogel |
CN102164606B (en) | 2008-09-30 | 2014-04-16 | 电气化学工业株式会社 | Light-stabilized pharmaceutical composition |
US20100098794A1 (en) | 2008-10-17 | 2010-04-22 | Armand Gerard | Topical anti-wrinkle and anti-aging moisturizing cream |
US20100111919A1 (en) | 2008-10-31 | 2010-05-06 | Tyco Healthcare Group Lp | Delayed gelation compositions and methods of use |
US9248165B2 (en) | 2008-11-05 | 2016-02-02 | Hancock-Jaffe Laboratories, Inc. | Composite containing collagen and elastin as a dermal expander and tissue filler |
AU2009311234B2 (en) | 2008-11-07 | 2013-05-02 | Klox Technologies Inc. | Combination of an oxidant and a photoactivator for the healing of wounds |
FR2938187B1 (en) | 2008-11-07 | 2012-08-17 | Anteis Sa | INJECTABLE COMPOSITION BASED ON HYALURONIC ACID OR ONE OF ITS HEAT-STERILIZED SALTS, POLYOLS AND LIDOCAINE |
ITRM20080636A1 (en) | 2008-11-28 | 2010-05-29 | Univ Palermo | PROCEDURE FOR THE PRODUCTION OF FUNCTIONAL DERIVATIVES OF HYALURONIC ACID AND RELATIVE HYDROGELS. |
WO2010065784A2 (en) | 2008-12-03 | 2010-06-10 | Jakk Group, Inc. | Methods, devices, and compositions for dermal filling |
SE533818C2 (en) | 2009-02-04 | 2011-01-25 | Roxtec Ab | Eccentric part of a pipe or cable entry |
JP2010202522A (en) | 2009-02-27 | 2010-09-16 | Shiseido Co Ltd | Salt-resistant thickener and cosmetic comprising the same |
JP2012519556A (en) | 2009-03-05 | 2012-08-30 | バイオミメティック セラピューティクス, インコーポレイテッド | Platelet-derived growth factor compositions and methods for treating osteochondral defects |
US20100249924A1 (en) | 2009-03-27 | 2010-09-30 | Allergan, Inc. | Bioerodible matrix for tissue involvement |
PL2236523T3 (en) | 2009-03-30 | 2018-07-31 | Scivision Biotech Inc. | Method for producing cross-linked hyaluronic acid |
WO2010115081A2 (en) | 2009-04-02 | 2010-10-07 | Allergan, Inc. | Hair-like shaped hydrogels for soft tissue augmentation |
US9371402B2 (en) | 2009-04-09 | 2016-06-21 | Scivision Biotech Inc. | Method for producing cross-linked hyaluronic acid |
US20110189292A1 (en) | 2009-04-20 | 2011-08-04 | Allergan, Inc. | Dermal fillers comprising silk fibroin hydrogels and uses thereof |
US20110111031A1 (en) | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
US20110052695A1 (en) | 2009-04-20 | 2011-03-03 | Allergan, Inc. | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof |
ES2414879T4 (en) | 2009-04-20 | 2013-10-30 | Allergan, Inc. | Silk fibroin hydrogels and their uses |
US9173975B2 (en) | 2009-04-24 | 2015-11-03 | Ingeneron, Inc. | Reparative cell delivery via hyaluronic acid vehicles |
US9101538B2 (en) | 2009-05-20 | 2015-08-11 | Donna M. Tozzi | Injectable amino-acid composition |
WO2010136585A2 (en) | 2009-05-29 | 2010-12-02 | Galderma Research & Development | Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid |
IT1395392B1 (en) | 2009-08-27 | 2012-09-14 | Fidia Farmaceutici | VISCOELASTIC FROSTS LIKE NEW FILLERS |
WO2011027790A1 (en) | 2009-09-03 | 2011-03-10 | 株式会社林原生物化学研究所 | Powder containing anhydrous crystals of 2-o-α-d-glucosyl-l-ascorbic acid, manufacturing method therefor, and use thereof |
RU2012122983A (en) | 2009-10-26 | 2014-01-27 | Галдерма Фарма С.А. | METHOD FOR TREATMENT AND PREVENTION OF ACUTE ERYTHEMA |
KR101122163B1 (en) | 2009-12-01 | 2012-03-16 | (주)셀인바이오 | Hyaluronic acid derivative with atopic dermatitis treating effect and method of preparing the same |
EP2512516B1 (en) | 2009-12-18 | 2016-02-17 | The Governing Council Of The University Of Toronto | Injectable polymer composition for use as a cell delivery vehicle |
US8790683B2 (en) | 2009-12-22 | 2014-07-29 | National Cheng Kung University | Cell tissue gel containing collagen and hyaluronan |
US20110171286A1 (en) | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9114188B2 (en) * | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US20110171310A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use |
US20110171311A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US8801682B2 (en) | 2010-01-27 | 2014-08-12 | Human Med Ag | Apparatus for separating tissue cells from a fluid |
CA2792729C (en) | 2010-03-12 | 2016-06-28 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
CA2794254C (en) | 2010-03-22 | 2018-09-04 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
ES2368307B1 (en) | 2010-04-28 | 2012-10-17 | Universidade De Santiago De Compostela | HYDROGELS ELABORATED BASED ON ANIONIC POLYMERS OF NATURAL ORIGIN. |
US20110295238A1 (en) | 2010-05-26 | 2011-12-01 | Human Med Ag | Device for fluid jet-supported separation and suctioning of tissue cells from a biological structure |
KR20110138765A (en) | 2010-06-22 | 2011-12-28 | (주)차바이오앤디오스텍 | Composite filler comprising cells isolated from human adipose tissue and hyaluronic acid derivative |
US9017712B2 (en) | 2010-07-12 | 2015-04-28 | Shin Poong Pharmaceutical Co., Ltd. | Filler composition for tissue reinforcement |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8741281B2 (en) | 2010-08-19 | 2014-06-03 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8697056B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
WO2012033218A1 (en) | 2010-09-07 | 2012-03-15 | 株式会社林原生物化学研究所 | HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, POWDER CONTAINING HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, METHOD FOR PRODUCING THE HYDROUS CRYSTALS, METHOD FOR PRODUCING THE POWDER, USE OF THE HYDROUS CRYSTALS, AND USE OF THE POWDER |
EP2979709B1 (en) | 2010-10-20 | 2017-08-02 | Allergan Holdings France S.A.S. | Threads of cross-linked hyaluronic acid and use thereof |
DE102011080218B4 (en) | 2010-10-20 | 2014-11-20 | Human Med Ag | Method and apparatus for separating adult stem cells from adipose tissue |
US9299476B2 (en) | 2010-10-22 | 2016-03-29 | Newsouth Innovations Pty Limited | Polymeric material |
FR2968306B1 (en) | 2010-12-06 | 2014-02-28 | Teoxane | PROCESS FOR PREPARING RETICULATED GEL |
FR2968305B1 (en) | 2010-12-06 | 2014-02-28 | Teoxane | PROCESS FOR PREPARING RETICULATED GEL |
EP2484387A1 (en) | 2011-02-03 | 2012-08-08 | Q-Med AB | Hyaluronic acid composition |
EP2678049A1 (en) | 2011-02-22 | 2014-01-01 | Merz Pharma GmbH & Co. KGaA | In situ formation of a filler |
RU2599252C2 (en) | 2011-03-07 | 2016-10-10 | Хаясиба Ко., Лтд. | Method for producing 2-o-alpha-d-glucosyl-l-ascorbic acid anhydrous crystal-containing powder |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) * | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
WO2013009102A2 (en) | 2011-07-13 | 2013-01-17 | (주)차바이오앤디오스텍 | Cartilage cell treating agent comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord |
WO2013015579A2 (en) | 2011-07-26 | 2013-01-31 | (주)차바이오앤디오스텍 | Medical composite organic material including collagen and hyaluronic acid derivatives |
KR102034645B1 (en) | 2011-07-26 | 2019-10-22 | 주식회사 차메디텍 | Medicinal Composite Biomaterial Comprising Collagen and Hyaluronic Acid Derivative |
US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US20130116190A1 (en) | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Hyaluronic acid-collagen matrices for tissue engineering |
US20130116411A1 (en) | 2011-09-06 | 2013-05-09 | Allergan, Inc. | Methods of making hyaluronic acid/collagen compositions |
US20130129835A1 (en) | 2011-09-06 | 2013-05-23 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
WO2013067293A1 (en) | 2011-11-04 | 2013-05-10 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
HUE050947T2 (en) | 2011-12-08 | 2021-01-28 | Allergan Ind Sas | Dermal filler compositions |
WO2013113587A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Hyperbranched polymers for modifying the toughness of hardened epoxy resin systems |
US20140011980A1 (en) | 2012-07-03 | 2014-01-09 | Allergan, Inc. | Methods for sterilizing compositions and resulting compositions |
ES2445492B1 (en) | 2012-08-01 | 2014-12-12 | San Juan Amazonía Europa, S.L. | Antioxidant compositions of a product obtained from the fruit of camu camu |
US10894062B2 (en) | 2012-08-10 | 2021-01-19 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
WO2016051219A1 (en) | 2014-09-30 | 2016-04-07 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
-
2010
- 2010-02-26 US US12/714,377 patent/US20110172180A1/en not_active Abandoned
-
2012
- 2012-05-24 US US13/479,551 patent/US8946192B2/en active Active
- 2012-11-13 US US13/675,993 patent/US9333160B2/en active Active
-
2016
- 2016-04-14 US US15/099,016 patent/US9855367B2/en active Active
-
2017
- 2017-11-29 US US15/825,465 patent/US10220113B2/en active Active
-
2019
- 2019-03-01 US US16/290,274 patent/US10806821B2/en active Active
-
2020
- 2020-10-06 US US17/064,527 patent/US20210077658A1/en not_active Abandoned
-
2023
- 2023-01-10 US US18/095,478 patent/US20230158203A1/en active Pending
Patent Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2128827A (en) * | 1938-03-09 | 1938-08-30 | Frank B Killian | Method and apparatus for manufacturing thin rubber articles |
US3548056A (en) * | 1966-06-30 | 1970-12-15 | Colgate Palmolive Co | Skin protecting composition containing a water - soluble partially degraded protein |
US3763009A (en) * | 1970-10-05 | 1973-10-02 | Hayashibara Co | Synthesis process for the production of ascorbic acid glucoside |
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4060081A (en) * | 1975-07-15 | 1977-11-29 | Massachusetts Institute Of Technology | Multilayer membrane useful as synthetic skin |
US4140537A (en) * | 1975-10-22 | 1979-02-20 | Collagen Corporation | Aqueous collagen composition |
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
US4279812A (en) * | 1979-09-12 | 1981-07-21 | Seton Company | Process for preparing macromolecular biologically active collagen |
US4273705A (en) * | 1979-10-04 | 1981-06-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preparing collagen filaments for use in medical treatments |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4501306A (en) * | 1982-11-09 | 1985-02-26 | Collagen Corporation | Automatic syringe filling system |
US4716154A (en) * | 1984-06-08 | 1987-12-29 | Pharmacia Ab | Gel of crosslinked hyaluronic acid for use as a vitreous humor substitute |
US4886787A (en) * | 1984-07-23 | 1989-12-12 | Pharmacia Ab | Method of preventing adhesion between body tissues, means for preventing such adhesion, and process for producing said means |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4636524A (en) * | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4713448A (en) * | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
US4642117A (en) * | 1985-03-22 | 1987-02-10 | Collagen Corporation | Mechanically sheared collagen implant material and method |
US5278059A (en) * | 1985-12-04 | 1994-01-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaki Kenkyujo | Polypeptide possessing cyclomaltodextrin glucanotransferase activity |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US6767924B2 (en) * | 1986-12-23 | 2004-07-27 | Tristrata Technology, Inc. | Method of using hydroxycarboxylic acids or related compounds for treating skin changes associated with intrinsic and extrinsic aging |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5091171A (en) * | 1986-12-23 | 1992-02-25 | Yu Ruey J | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5091171B1 (en) * | 1986-12-23 | 1995-09-26 | Ruey J Yu | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US4896787A (en) * | 1987-08-14 | 1990-01-30 | Genus International | Article with resilient hinges becoming rigid under tension |
US5643464A (en) * | 1988-11-21 | 1997-07-01 | Collagen Corporation | Process for preparing a sterile, dry crosslinking agent |
US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
US5565519A (en) * | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5328955A (en) * | 1988-11-21 | 1994-07-12 | Collagen Corporation | Collagen-polymer conjugates |
US5009013A (en) * | 1988-11-30 | 1991-04-23 | Wiklund Henry W | Device in machines for the marking of workpieces |
US5087446A (en) * | 1989-02-15 | 1992-02-11 | Chisso Corporation | Skin cosmetics |
US5616611A (en) * | 1989-05-19 | 1997-04-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-glycosyl-L-ascorbic acid, and its preparation and uses |
US5137723A (en) * | 1989-05-19 | 1992-08-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α-Glycosyl-L-ascorbic acid, and its preparation and uses |
US6013679A (en) * | 1989-08-01 | 2000-01-11 | Anika Research, Inc. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US6013679C1 (en) * | 1989-08-01 | 2001-06-19 | Anika Res Inc | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US5356883A (en) * | 1989-08-01 | 1994-10-18 | Research Foundation Of State University Of N.Y. | Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use |
US5886042A (en) * | 1989-08-15 | 1999-03-23 | Tristrata Technology, Inc. | Amphoteric compostion and polymeric forms of alpha hydroxyacids, and their therapeutic use |
US5407812A (en) * | 1989-10-21 | 1995-04-18 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline 2-O-α-D-glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5432161A (en) * | 1989-10-21 | 1995-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline 2-O-α-d-glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5508391A (en) * | 1989-10-21 | 1996-04-16 | Kabushiki Kaisha Hayashibara | Crystalline 2-O-α-D-glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5843907A (en) * | 1989-10-21 | 1998-12-01 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pharmaceutical composition containing 2-O-α-d-glucopyranosyl-l-ascorbic acid |
US5084563A (en) * | 1989-10-21 | 1992-01-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Crystalline 2-O-α-D-glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US4996787A (en) * | 1990-05-29 | 1991-03-05 | Jack N. Holcomb | SigSauer pistol with concealed radio transmitter |
US5399351A (en) * | 1990-07-09 | 1995-03-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5246698A (en) * | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5143724A (en) * | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5827529A (en) * | 1991-03-30 | 1998-10-27 | Teikoku Seiyaku Kabushiki Kaisha | External preparation for application to the skin containing lidocaine |
US5314874A (en) * | 1991-04-19 | 1994-05-24 | Koken Co., Ltd. | Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen |
US5272136A (en) * | 1991-10-12 | 1993-12-21 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 5-0-α-D-Glucopyranosyl-L-ascorbic acid, and its preparation and uses |
US5252722A (en) * | 1991-10-21 | 1993-10-12 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | 5-O-α-D-glucopyranosyl-L-ascorbic acid |
US5468850A (en) * | 1991-10-23 | 1995-11-21 | Kabushiki Kaisha Hayashibara | Process for preparing high 2-O-α-D-glucopyranosyl-L-ascorbic acid content product |
US5338420A (en) * | 1992-01-30 | 1994-08-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process for preparing high α-glycosyl-L-ascorbic acid, and separation system for the process |
US5428024A (en) * | 1992-02-28 | 1995-06-27 | Collagen Corporation | High concentration homogenized collagen compositions |
US5980930A (en) * | 1993-01-20 | 1999-11-09 | Bristol-Myers Squibb Company | Fibres |
US5633001A (en) * | 1993-03-19 | 1997-05-27 | Medinvent | Composition and a method for tissue augmentation |
US5531716A (en) * | 1993-09-29 | 1996-07-02 | Hercules Incorporated | Medical devices subject to triggered disintegration |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5823671A (en) * | 1994-05-10 | 1998-10-20 | Collagen Corporation | Apparatus and method of mixing materials in a sterile environment |
US5616689A (en) * | 1994-07-13 | 1997-04-01 | Collagen Corporation | Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation |
US5824333A (en) * | 1994-10-18 | 1998-10-20 | Ethicon, Inc. | Injectable liquid copolymers for soft tissue repair and augmentation |
US6544503B1 (en) * | 1995-06-06 | 2003-04-08 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US5571503A (en) * | 1995-08-01 | 1996-11-05 | Mausner; Jack | Anti-pollution cosmetic composition |
US6335035B1 (en) * | 1995-09-29 | 2002-01-01 | L.A.M. Pharmaceutical Corporation | Sustained release delivery system |
US5880107A (en) * | 1995-12-22 | 1999-03-09 | Chemedica S.A. | Sodium hyaluronate based ophthalmic formulation for use in eye surgery |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6224857B1 (en) * | 1996-10-17 | 2001-05-01 | Fidia, S.P.A. | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics |
US6383218B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Sclero-ceratectomy implant for descemet's membrane |
US6383219B1 (en) * | 1997-02-17 | 2002-05-07 | Corneal Industrie | Implant for deep sclerectomy |
US5935164A (en) * | 1997-02-25 | 1999-08-10 | Pmt Corporaton | Laminated prosthesis and method of manufacture |
US6716251B1 (en) * | 1997-06-13 | 2004-04-06 | Aventis Pharmaceuticals Holdings, Inc. | Implant for subcutaneous or intradermal injection |
US7192984B2 (en) * | 1997-06-17 | 2007-03-20 | Fziomed, Inc. | Compositions of polyacids and polyethers and methods for their use as dermal fillers |
US6630486B1 (en) * | 1997-09-22 | 2003-10-07 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US20020151711A1 (en) * | 1998-05-29 | 2002-10-17 | Pe Corporation (Ny) | Nucleotide compounds including a rigid linker |
US6685963B1 (en) * | 1998-07-01 | 2004-02-03 | Corneal Industrie | Diphasic injection composition containing dispersed and continuous phases useful for reparative and plastic surgery |
US6627620B1 (en) * | 1998-12-18 | 2003-09-30 | Per Julius Nielsen | Composition set and kit for use in intraocular surgery |
US6767928B1 (en) * | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
US6521223B1 (en) * | 2000-02-14 | 2003-02-18 | Genzyme Corporation | Single phase gels for the prevention of adhesions |
US6418934B1 (en) * | 2000-04-19 | 2002-07-16 | Sae-Hoon Chin | Use of polymeric materials for enlarging human glans and method of performing a surgery for enlarging a human glans with the said materials |
US6921819B2 (en) * | 2000-07-19 | 2005-07-26 | Laboratoires D'esthetique Appliquee | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof |
US6939562B2 (en) * | 2000-08-30 | 2005-09-06 | Depuy Acromed, Inc. | Collagen/polysaccharide bilayer matrix |
US6893466B2 (en) * | 2000-08-30 | 2005-05-17 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
US6979440B2 (en) * | 2001-01-29 | 2005-12-27 | Salvona, Llc | Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric |
US7119062B1 (en) * | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
US7314636B2 (en) * | 2001-06-29 | 2008-01-01 | Medgraft Microtech, Inc. | Biodegradable injectable implants containing glycolic acid |
US20060174758A1 (en) * | 2003-03-19 | 2006-08-10 | Josef Beck | Pressure pin and axial piston machine having said pressure pin |
US7741476B2 (en) * | 2003-04-10 | 2010-06-22 | Allergan Industrie, Sas | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and hydrogels thus obtained |
US20060194758A1 (en) * | 2003-04-10 | 2006-08-31 | Pierre Lebreton | Cross-linking of low and high molecular weight polysaccharides preparation of injectable monophase hydrogels and polysaccharides and dydrogels thus obtained |
US7166570B2 (en) * | 2003-11-10 | 2007-01-23 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US7902171B2 (en) * | 2004-01-14 | 2011-03-08 | Reinmueller Johannes | Composition for treating inflammatory diseases |
US20080268547A1 (en) * | 2004-04-09 | 2008-10-30 | Board Of Regents, The University Of Texas System | Systems and Methods for Indicating Oxidation of Consumer Products |
US20060040894A1 (en) * | 2004-08-13 | 2006-02-23 | Angiotech International Ag | Compositions and methods using hyaluronic acid |
US20090018102A1 (en) * | 2005-12-21 | 2009-01-15 | Galderma Research & Development | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith |
US20090022808A1 (en) * | 2007-05-23 | 2009-01-22 | Allergan, Inc. | Coated Hyaluronic Acid Particles |
US20090036403A1 (en) * | 2007-07-30 | 2009-02-05 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US20090093755A1 (en) * | 2007-10-09 | 2009-04-09 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
US20090143331A1 (en) * | 2007-11-30 | 2009-06-04 | Dimitrios Stroumpoulis | Polysaccharide gel formulation having increased longevity |
US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
US20090155314A1 (en) * | 2007-12-12 | 2009-06-18 | Ahmet Tezel | Dermal filler |
Non-Patent Citations (1)
Title |
---|
Hayashibara; AA2G [online]; 23 September 2007 [retrieved on 17 January 2012]; retrieved from the Internet: . * |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110077737A1 (en) * | 2007-07-30 | 2011-03-31 | Allergan, Inc. | Tunably Crosslinked Polysaccharide Compositions |
US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8703118B2 (en) | 2007-10-09 | 2014-04-22 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US8513216B2 (en) | 2007-11-30 | 2013-08-20 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US8822676B2 (en) | 2008-08-04 | 2014-09-02 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US20150320743A1 (en) * | 2009-05-29 | 2015-11-12 | Sylviane Villard | Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10220113B2 (en) | 2010-01-13 | 2019-03-05 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10111984B2 (en) | 2010-03-22 | 2018-10-30 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US11154481B2 (en) * | 2011-02-03 | 2021-10-26 | Q-Med Ab | Hyaluronic acid composition |
US20200261343A1 (en) * | 2011-02-03 | 2020-08-20 | Q-Med Ab | Hyaluronic acid composition |
US20190000740A1 (en) * | 2011-02-03 | 2019-01-03 | Q-Med Ab | Hyaluronic acid composition |
US10098961B2 (en) * | 2011-02-03 | 2018-10-16 | Q-Med Ab | Hyaluronic acid composition |
US20220000752A1 (en) * | 2011-02-03 | 2022-01-06 | Q-Med Ab | Hyaluronic acid composition |
US20140039061A1 (en) * | 2011-02-03 | 2014-02-06 | Q-Med Ab | Hyaluronic acid composition |
US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
RU2626513C2 (en) * | 2011-09-14 | 2017-07-28 | Аллерган, Инк. | Dermal filler composition for small wrinkles treating |
US10201535B2 (en) | 2011-11-10 | 2019-02-12 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
US9402799B2 (en) * | 2012-08-29 | 2016-08-02 | Laboratories Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
US10058499B2 (en) | 2012-08-29 | 2018-08-28 | Laboratoires Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
US20140088037A1 (en) * | 2012-08-29 | 2014-03-27 | Laboratoires Vivacy | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate |
WO2014173941A3 (en) * | 2013-04-26 | 2014-12-31 | Auriga International | Method for obtaining a stable gel of hyaluronic acid and of a free form of vitamin c and/or a salt thereof |
US9669007B2 (en) | 2013-04-26 | 2017-06-06 | Auriga International | Method for obtaining a stable gel of hyaluronic acid and of a free form of vitamin C and/or a salt thereof |
BE1022012B1 (en) * | 2013-04-26 | 2016-02-04 | Auriga International | STABLE GEL OF HYALURONIC ACID AND A FREE FORM OF VITAMIN C AND / OR ONE OF ITS SALTS |
CN105377229A (en) * | 2013-04-26 | 2016-03-02 | 奧丽嘉国际有限公司 | Method for obtaining a stable gel of hyaluronic acid and of a free form of vitamin c and/or a salt thereof |
WO2014173941A2 (en) * | 2013-04-26 | 2014-10-30 | Auriga International | Method for obtaining a stable gel of hyaluronic acid and of a free form of vitamin c and/or a salt thereof |
WO2015164533A1 (en) * | 2014-04-22 | 2015-10-29 | Allergan, Inc. | Dry dermal filler compositions and methods of reconstitution |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
WO2016128783A1 (en) * | 2015-02-09 | 2016-08-18 | Allergan Industrie Sas | Compositions and methods for improving skin appearance |
EP3988078A1 (en) * | 2015-02-09 | 2022-04-27 | Allergan Industrie, SAS | Compositions and methods for improving skin appearance |
EP3256097B1 (en) | 2015-02-09 | 2022-01-05 | Allergan Industrie, SAS | Compositions and methods for improving skin appearance |
CN114042189A (en) * | 2021-11-09 | 2022-02-15 | 无锡本物医疗器械有限公司 | Injection type filler composition and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US10806821B2 (en) | 2020-10-20 |
US9333160B2 (en) | 2016-05-10 |
US8946192B2 (en) | 2015-02-03 |
US20160220729A1 (en) | 2016-08-04 |
US10220113B2 (en) | 2019-03-05 |
US20180078674A1 (en) | 2018-03-22 |
US20190192732A1 (en) | 2019-06-27 |
US20230158203A1 (en) | 2023-05-25 |
US20120232030A1 (en) | 2012-09-13 |
US9855367B2 (en) | 2018-01-02 |
US20130072453A1 (en) | 2013-03-21 |
US20210077658A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10806821B2 (en) | Heat stable hyaluronic acid compositions for dermatological use | |
US20120225842A1 (en) | Hyaluronic acid compositions for dermatological use | |
JP6749993B2 (en) | Skin filler composition containing antioxidants | |
US8394784B2 (en) | Polysaccharide gel formulation having multi-stage bioactive agent delivery | |
KR102161861B1 (en) | Dermal filler compositions for fine line treatment | |
AU2008331602B2 (en) | Polysaccharide gel formulation | |
EP3590495A1 (en) | Dermal filler compositions including antioxidants | |
AU2018260925B2 (en) | Polysaccharide gel formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALLERGAN, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOUSSE, CECILE;LEBRETON, PIERRE F.;PROST, NICOLAS;SIGNING DATES FROM 20100315 TO 20100318;REEL/FRAME:024132/0356 Owner name: ALLERGAN INDUSTRIE, SAS, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOUSSE, CECILE;LEBRETON, PIERRE F.;PROST, NICOLAS;SIGNING DATES FROM 20100315 TO 20100318;REEL/FRAME:024132/0356 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALLERGAN INDUSTRIE, S.A.S., FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLERGAN, INC.;REEL/FRAME:032202/0612 Effective date: 20131022 |